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Background: Similar to other infectious organisms, Mycobacterium tuberculosis (M. 
tuberculosis) is known to develop drug resistance via acquisition of mutations in its 
deoxyribonucleic acid (DNA).  These genomic mutations often arise during the course of drug 
therapy as the result of non-compliance or inappropriate drug regimens, which create selective 
drug pressure that leads to the development of resistant strains. Although mutations that cause 
resistance to first-line anti-tuberculosis drugs have been well characterized, there is a significant 
amount of drug resistance in M. tuberculosis for which the genetic basis has not been defined.  
Knowledge of resistance conferring mutations is important for the treatment of drug-resistant 
tuberculosis (TB). Conventional phenotypic drug susceptibility testing (DST) in M. tuberculosis 
is a lengthy, cumbersome and requires laboratory containment. Therefore, molecular methods to 
determine drug resistance rapidly are highly desirable. 
 
Method: To identify novel mutations associated with drug resistance in TB, we exploited the 
results of a whole genome sequencing (WGS) study of clinical M. tuberculosis isolates from 
KwaZulu-Natal (Cohen et al., 2015). We selected loss-of-function (LOF) mutations that were 
associated with resistance. Using isogenic strains with single genes inactivated, DSTs, growth 
inhibition and complementation assays we functionally tested if these LOF mutations caused 
resistance. 
 
Results: LOF mutations in ald, encoding L-alanine dehydrogenase occurred only in drug-
resistant clinical strains. The ald LOF mutations occurred frequently within resistant clinical 
isolates from Lineage 4. The Δald conferred a growth advantage in a single gene knockout model 
in the presence of D-cycloserine. Minimum inhibitory concentration (MIC) measurements of 
clinical and laboratory strains with mutations in ald displayed increased resistance to D-
cycloserine when treated in vitro. With complementation analyses of the mutant with the cognate 
M. tuberculosis ald gene we confirmed susceptibility to D-cycloserine was partially restored, in 
this way confirming the association of the ald knock-out strain with D-cycloserine resistance.  
 
Conclusion: LOF of ald may represent a novel mechanism of resistance to D-cycloserine. Whole 
genome association studies can identify novel drug resistance conferring mutations which will 







Approximately one third of the world’s population is infected with M. tuberculosis, the etiologic 
agent responsible for TB (WHO, 2015). While many individuals who harbour M. tuberculosis 
never develop active disease, TB is often a lethal disease and is estimated to have been responsible 
for approximately 1.5 million deaths in the year 2015 (WHO, 2015). 
 
Antibiotic therapy can be effective at treating the disease, however, the emergence of drug-
resistant TB has made control efforts more difficult. Since its initial documentation in the 1940s 
(Schatz and Waksman, 1944, Crofton and Mitchison, 1948), drug-resistant TB has increased 
globally.  In 2014, the World Health Organization (WHO) reported nearly 480,000 new cases of 
multidrug-resistant TB (MDR-TB) (WHO, 2015). MDR-TB is defined as M. tuberculosis with 
resistance to isoniazid (INH) and rifampicin (RIF). Regrettably, South Africa has one of the 
highest rates of TB globally, and one of the highest burdens of MDR-TB in the world (WHO, 
2015). 
 
Further along the scale of drug-resistant TB is the existence of extensively drug-resistant TB 
(XDR-TB). XDR-TB is defined as M. tuberculosis that is resistant to both INH and RIF, but also 
two other classes of anti-tuberculosis therapy, namely a fluoroquinolone and at least one of the 
injectable second-line drugs (Dahle, 2006). Second-line treatment is very expensive and more 
challenging to patient care as some of these drugs need to be administered intravenously (Pooran 
et al., 2013, Pietersen et al., 2014). TB treatment is often associated with serious medical 
complications due to certain drugs being very toxic and having harsh side effects (Sacchettini et 
al., 2008, Högberg et al., 2010).  
 
Diagnostic limitations are a major barrier to the identification and subsequent management of 
drug-resistant TB. With a replication rate of approximately 24 hours, M. tuberculosis is a 
particularly slow growing bacterium (Ginsberg and Spigelman, 2007). Primary isolation using 
solid or liquid culture medium takes three to six weeks for isolation (Naveen and Peerapur, 2012). 
The slow growth rate of M. tuberculosis also means that standard phenotypic laboratory DST can 
take an additional six weeks to appropriately identify M. tuberculosis and determine a clinical 
isolate’s individual drug susceptibility pattern (Garg et al., 2003, Parrish and Carrol, 2008). 
Clinically, these delays translate into late diagnosis of drug-resistant TB and deferred initiation 
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of an efficacious drug regimen, potentially leading to amplification of resistance, additional 
person-to-person spread of drug-resistant TB as well as increased morbidity and mortality (Garg 
et al., 2003).   
 
Recently developed genotypic tools have improved diagnostic efforts.  One such molecular test, 
the Xpert MTB/RIF assay has been recently implemented as a “point of care test” for the 
simultaneous detection of M. tuberculosis and diagnosis of RIF resistance in under two hours 
(Boehme et al., 2010). This test has been shown to have excellent sensitivity in smear-positive 
pulmonary TB (Boehme et al., 2010). These assays have improved TB case detection among both 
drug susceptible and MDR-TB.  While Xpert MTB/RIF detects RIF resistance, it is unable to 
distinguish MDR from XDR-TB as well as being unable to detect INH and other mono-resistances 
(Evans, 2011). The Xpert MTB/RIF assay is less sensitive than culture therefore culture based 
assays are still required, and culture still remains the standard for TB diagnosis and DST (Evans, 
2011).  
 
Another molecular genetic tool used for the detection of resistance to first and second-line anti 
TB drugs of M. tuberculosis complex is the GenoType MTBDRplus and GenoType MTBDRsl 
(Hillemann et al., 2009, Miotto et al., 2008, Hillemann et al., 2005). These tests are based on a 
DNA strip technology that can be performed from pulmonary patient specimen and from culture 
material (Lacoma et al., 2008). Results are obtained in approximately five hours compared to one 
to two months with conventional methods. The GenoType MTBDRsl test however, is only able 
to manipulate a limited number of resistance conferring mutations and this assay is only able to 
detect one in three to four cases of XDR-TB (Theron et al., 2014). The GenoType MTBDRplus 
and GenoType MTBDRsl is less sensitive in smear negative patients and requires confirmatory 
culture methods (Tomasicchio et al., 2016). Thus, these tools are still not optimal, and new 
improved therapeutic and diagnostic interventions are still urgently required to effectively halt 
the drug-resistant TB epidemic. 
 
While current genotypic tests are useful, these tests are only able to identify known resistance 
mutations. As indicated above the GenoType MTBDRsl has limited sensitivity for 
fluoroquinolone and aminoglycoside resistance indicating, there is still a significant amount of 
drug resistance in M. tuberculosis for which the molecular determinants are unknown (Zhang and 
Yew, 2009, Desjardins et al., 2016) even for these standard second-line drugs. Thus, it is likely 
that there are yet unidentified M. tuberculosis genes that confer drug resistance to these agents as 
well as to other second-line drugs where the resistance mechanisms have been less 
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comprehensively studied. Recent interest in WGS on sputum or on cultured isolates (Brown et 
al., 2015) has been increasing, this technology could potentially generate a full catalogue of all 
resistance conferring mutations and allow us to fully comprehend the genetic foundation of drug 
resistance (Köser  et al., 2013, Coll et al., 2015, Starks et al., 2015, Colijn and Cohen, 2016). 
 
The first M. tuberculosis genome to be successfully sequenced was the laboratory strain H37Rv 
by Cole and colleagues in 1998 (Cole et al., 1998). In this important undertaking, it was revealed 
that the M. tuberculosis genome contains 4,411,529 base pairs and approximately 4000 genes. 
While H37Rv is a fully drug susceptible strain, WGS has advanced dramatically since then and 
increasing numbers of studies of clinical isolates are beginning to shed additional light on the 
genetic diversity of drug susceptible and drug-resistant M. tuberculosis (Farhat et al., 2013, Köser  
et al., 2013, Zhang et al., 2013, Casali et al., 2014, Cohen et al., 2015, Farhat et al., 2016) 
   
 
Figure 1.1: The M. tuberculosis H37Rv genome (Cole et al., 1998). H37Rv is GC-rich genome containing 
4,411,529 base pairs. This genome was reported to encode 4057 genes, of which 4007 encoding RNA for 
proteins and 50 encoding for RNA molecules 
 
Various studies using WGS have shown that for the first-line drugs INH and RIF; genome 
sequencing can predict a drug susceptibility phenotype determined in culture with high specificity 
and sensitivity (Coll et al., 2015, Walker et al., 2015). For example, a study conducted by Coll et 
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al., (2015) utilized WGS derived mutations as a predictor for drug resistance. In this study in 
silico inferred resistance phenotypes were compared to traditional DST. From their mutation 
analysis the authors were able to predict a 96.0% and 92.8% of resistance to RIF and INH 
respectively when compared to conventional methods (Coll et al., 2015). The comparison was 
less successful in other first-line drugs namely, pyrazinamide (PZA), as these strains possessed a 
resistant profile which was not recognizable by the genome analysis, although there are still 
reliability issues with DST for this drug. In ethambutol, however, it was found that susceptible 
strains possessed mutations that had previously been associated with resistance. Upon extending 
their analysis to second-line drugs, they found that only 39% of capreomycin resistant strains 
were unable to be identified by use of the authors in silico genome analysis. For the drug 
moxifloxacin, of the 42 strains that were tested, ten were classified as phenotypically resistant by 
conventional DST methods, but only six of which were identified as resistant by the mutation 
analysis (Coll et al., 2015).  
 
In another study, Farhat et al., (2013) developed a phyC method to identify mutations significantly 
evolving more frequently on drug resistance branches of the phylogenetic tree as compared to 
drug sensitive mutations. This was done, utilizing a permutation test to control for phylogenetic 
tree topology and the distribution of phenotypic resistances (Farhat et al., 2013). The authors 
discovered that mutations in the gene ponA1 conferred a modest growth advantage in the presence 
of low levels of RIF (Farhat et al., 2013). Zhang et al., (2013) developed a method that pre-filtered 
single nucleotide polymorphisms (SNPs) identified as phylogenetic i.e. inherited and not related 
to drug resistance (Zhang et al., 2013). The authors then identified genes with either an 
overabundance of non-phylogenetic mutations in general, or a greater number of non-
phylogenetic mutations in drug-resistant strains than in drug sensitive ones (Zhang et al., 2013). 
Both studies robustly recovered known resistance mechanisms for a number of drugs, and 
identified novel mutations associated with resistance. However, only the ponA1 mutation was 
characterised functionally to show that it contributed to RIF resistance so it is unknown whether 
any of the other identified mutations actually confer resistance. This illustrates how important it 
is to use molecular studies to characterise mutations identified in WGS association studies. 
 
Another approach has been to use targeted sequencing of known resistance conferring loci (Farhat 
et al., 2016). Farhat et al., (2016), sequenced 1397 clinical strains and could predict >90% 
resistance to RIF and INH. However, the results of this study further illustrated that for second-
line drugs a considerable proportion of drug resistance is not explained by known mutations.  
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Further elucidation of the genomic basis of resistance is therefore needed to develop much-needed 
improvements in the design of rapid molecular diagnostics. To develop these assays, we must 
identify all the relevant genes and genetic mutations that confer resistance. This will only be 
achieved by combining WGS studies with functional genomics.  
In this masters study we used data from a genome wide association study to identify mutations 
associated with resistance. We focussed on frameshift mutations and intragenic insertions or 
deletions which we termed LOF mutations as these are guaranteed to inactivate the gene and result 
in a loss of gene function. In contrast the effects of non-synonymous SNPs on gene function are 
hard to predict in silico. Utilizing genomes from this completed WGS transmission study (Cohen 
et al., 2015), we selected LOF mutations associated with resistance. Screening isogenic strains 
with insertional inactivation of individual genes we were able to identify a novel mechanism by 
which M. tuberculosis gains resistance to D-cycloserine. We employed molecular techniques to 
determine that this ald LOF mutation caused resistance to D-cycloserine. To date, little is known 
about clinical isolates and resistance to D-cycloserine. Given the toxicities associated with D-
cycloserine (Kendig et al., 1956, Murray, 1956, Bankier, 1965, Yew et al., 1993, Cunha, 2001, 
Torun et al., 2005, Mitnick et al., 2008) and technical difficulties (Kam et al., 2010) in performing 





1.2 D-cycloserine  
1.2.1 Discovery 
D-cycloserine also known as oxazolidine, is an anti-tubercular drug that was initially discovered 
as a metabolic product of Streptomyces in 1952 (Kuehl Jr et al., 1955).  D-cycloserine is an 
analogue of D-alanine, and was found to be produced by Streptomyces lavendulae and 
Streptomyces garyphalus (Harris et al., 1955, Kuehl Jr et al., 1955, Zawadzke et al., 1991). D-
cycloserine exists in a cyclic form and is obtained naturally as a d-isomer (Lee et al., 1998).  
 
1.2.2 Structure of D-cycloserine  
 
Figure 1.2: Chemical structure of D-cycloserine. This drug belongs to a group of organic compounds 
termed alpha amino acids (Takahashi et al., 1981), that have their amino group attached to a carbon atom, 
which is adjacent to a carboxylate group (Takahashi et al., 1981).  
 
1.2.3 Mechanism of action 
Early studies provided insight into the mode of action of D-cycloserine (Pittillo and Foster, 1954, 
Bondi et al., 1957, Morrison, 1962, Zygmunt, 1963).  Pittillo and Foster.,(1954) demonstrated 
that D-alanine reversed the effects of D-cycloserine when added  to liquid cultures of Aerobacter 
aerogenes (Pittillo and Foster, 1954).  
 
Bondi et al.,(1957), showed in Staphylococcus aureus that alanine supplementation negated the 
effect of D-cycloserine (Bondi et al., 1957). This study deduced that D-cycloserine interferes with 
the alanine metabolism pathway (Bondi et al., 1957).  
 
Further studies conducted on Escherichia coli (E. coli) and S. aureus demonstrated that D-alanine 
was more effective at reversing the effects of D-cycloserine than L-alanine (Zygmunt, 1963). 
Work conducted on M. tuberculosis and Mycobacterium phlei also demonstrated that growth 
inhibition by D-cycloserine was reversed by  the addition of D-alanine (Morrison, 1962).  
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D-cycloserine is an analogue of D-alanine and is known to be an inhibitor of peptidoglycan cell 
wall biosynthesis (Caceres et al., 1997). Peptidoglycan is a composite polymer made up of glycan 
chains which are cross linked by short peptide chains (Typas et al., 2012, Barreteau et al., 2008). 
Peptidoglycan is an integral component of the bacterial cell wall including that of M. tuberculosis 
(Typas et al., 2012). In addition to providing architectural support, peptidoglycan is crucial for 
cell durability. Several potent antibiotics have also been known to target the synthesis of 
peptidoglycan, as peptidoglycan is an ideal target for drug design (Kieser and Rubin, 2014). 
Peptidoglycan is the backbone of bacterial cell wall, and is essential for cell wall biosynthesis and 




Figure 1.3: Chemical structure of D-alanine. D-cycloserine is the structural analogue of D-alanine 
(https://pubchem.ncbi.nlm.nih.gov/compound/D-alanine) 
 
D-cycloserine is involved in the competitive inhibition of two key enzymes in the alanine 
metabolism pathway. These two important enzymes were also found to be targets in initial studies 
conducted on E. coli (Neuhaus and Lynch, 1964, Reitz et al., 1967, Lambert and Neuhaus, 1972). 
The two enzymes, alanine racemase (encoded by alr) (Lambert and Neuhaus, 1972) and D-
alanine:D-alanine ligase  (encoded by ddlA) (Strominger et al., 1960, Prosser and de Carvalho, 
2013) are essential in the synthesis of peptidoglycan (Walsh, 1989).  Alanine racemase is essential 
for the conversion of L-alanine to D-alanine (Strych et al., 2001, LeMagueres et al., 2005). 
Bacteria use D-alanine for the synthesis of the peptidoglycan cell wall. Once D-alanine is created 
by alanine racemase, the D-alanine molecules are then joined to create a dipeptide. This D-
alanine:D-alanine dipeptide is created by a ligase enzyme D-alanine:D-alanine ligase which 
synthesizes the dipeptides and allows for further elongation to create the peptidoglycan cell wall 
(Bruning et al., 2011).  
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In earlier studies conducted on M. tuberculosis, alanine racemase and D-alanine:D-alanine ligase 
enzymes were proposed targets of D-cycloserine in mycobacteria (Reitz et al., 1967, David et al., 
1969). Studies conducted on M. smegmatis revealed that inactivation of the alanine racemase and 
D-alanine:D-alanine ligase enzymes result in susceptibility to D-cycloserine, and overexpression 
of alanine racemase is implicated in resistance to D-cycloserine (Zhang, 2005).  
 
1.2.4 Clinical Uses 
An oral bacteriostatic agent for the treatment of TB, D-cycloserine belongs to Group four of the 
World Health Organization categorization (WHO, 2008a).  As a second-line agent, D-cycloserine 
is commonly used in the treatment of MDR and XDR-TB (Caminero et al., 2010). An advantage 
of using D-cycloserine in the treatment of drug-resistant TB is that it has not shown to have cross 
resistance to other antibiotics (WHO, 2008b, Caminero et al., 2010). Beyond its anti-tubercular 
activity, D-cycloserine is also known to have broad-spectrum activity against gram-positive 
bacteria, including S. aureus and some gram-negative bacteria, including E. coli (Roze and 
Strominger, 1966, Lambert and Neuhaus, 1972).  
 
Terizidone is a derivative of D-cycloserine and structurally is formed by two molecules of D-
cycloserine joined by a molecule of terephtalic dialdehyde (Zitkova and Toušek, 1974). 
Terizidone is rapidly metabolised to form two molecules of D-cycloserine after administration to 
humans. Terizidone has similar activity to D-cycloserine in that it is used to treat patients with 
MDR and XDR-TB and is also an oral bacteriostatic drug.  Terizidone is administered to patients 
as it may have an improved safety profile and is a cheaper alternative in resource limited settings 









Figure 1.4: Chemical structure of Terizidone. This drug possesses double molecules of D-cycloserine 




1.2.5 Limitations of D-cycloserine chemotherapy 
While D-cycloserine is an effective antimicrobial in TB treatment, its severe toxicity limits its use 
(Cunha, 2001, Torun et al., 2005, Mitnick et al., 2008). D-cycloserine has been known to promote 
increased anxiety and depression in patients (Kendig et al., 1956, Murray, 1956). Side effects 
include drowsiness, vertigo, memory loss, psychosis, convulsion and seizures (Yew et al., 1993, 
Bankier, 1965).  
 
Phenotypic DST and current molecular testing for D-cycloserine resistance is not performed 
routinely by clinical laboratories due to instability of the drug (Kam et al., 2010) and due to 
difficulties with the assay. D-cycloserine is unstable in acidic conditions, but relatively stable 
under alkaline and neutral pH conditions (Woods, 2000, Kam et al., 2010). Therefore, use of 
freshly prepared solutions of D-cycloserine is recommended for determination of bacterial 
susceptibility, and complicates testing in clinical laboratories.  
 
Given the toxicities of D-cycloserine, it would be ideal to prescribe this drug only to individuals 
who harbor susceptible strains (Bastos et al., 2014, Cegielski et al., 2014). Rapid diagnostics that 
predict resistance to these drugs do not yet exist, therefore the development of molecular 
diagnostics that assess D-cycloserine resistance will allow for optimization of MDR and XDR 





1.3 Roles of D-alanine:D-alanine ligase and alanine racemase in the mechanisms of action 
and resistance to the peptidoglycan inhibitor D-cycloserine 
Multiple studies in different organisms have shown that D-cycloserine interferes with the 
metabolism and incorporation of D-alanine into the peptidoglycan cell wall. D-cycloserine has 
been shown to target the two enzymes, alanine racemase and the D-alanine:D-alanine ligase. Only 
recently have studies been carried out to determine which of these enzymes is the principle target 
in mycobacteria.  
 
1.3.1 D-alanine branch pathway of peptidoglycan biosynthesis 
Alanine racemase and D-alanine:D-alanine ligase function in attaining D-alanine from L-alanine 
into UDP-muramvl pentapeptide. D-alanine is the central molecule which functions in the 
crosslinking step of peptidoglycan assembly and is a key component in peptidoglycan synthesis 
(Feng and Barletta, 2003).  The pyridoxal phosphate-dependent alanine racemase catalyzes the 
conversion of L-alanine to D-alanine, while the ATP-dependent D-alanine:D-alanine ligase 
synthesizes the D-alanine:D-alanine dipeptide, which is incorporated into UDP-muramyl 
tripeptide by a D-alanine:D-alanine adding enzyme (MurF) (Feng and Barletta, 2003). These 
enzymes constitute the D-alanine branch pathway of peptidoglycan biosynthesis (Walsh, 1989).  
 
 
Figure 1.5: A diagrammatic representation showing the alanine metabolism pathway and targets of 
D-cycloserine in bacteria. Alanine racemase and D-alanine:D-alanine ligase are involved in the synthesis 
of peptidoglycan. Alanine racemase functions in converting L-alanine to D-alanine, which are joined to 
create a dipeptide. The dipeptide is formed by D-alanine:D-alanine ligase which allows for further 




1.3.2 D-cycloserine competitively inhibits alanine racemase and the D-alanine:D-alanine 
ligase 
The targets of D-cycloserine were initially elucidated in other bacteria. Experimental studies 
conducted on S. aureus demonstrated that D-cycloserine possessed the correct conformation that 
is required to bind L- and D-alanine on the enzyme surface. This was not demonstrated by L-
cycloserine. The authors showed that D-cycloserine played a role in the competitive inhibition of 
alanine racemase (Roze and Strominger, 1966). 
 
Studies conducted on E. coli showed that D-cycloserine can target both alanine racemase and D-
alanine:D-alanine ligase (Lambert and Neuhaus, 1972). Research conducted on D-cycloserine 
resistant mutants of Streptococcus gordonii also showed an overproduction of the alanine 
racemase and D-alanine:D-alanine ligase enzymes, in this way proposing that these two enzymes 
play a synergistic role against D-cycloserine inhibition (Reitz et al., 1967). 
 
These studies implicated both alanine racemase and D-alanine:D-alanine ligase as potential D-
cycloserine drug targets in mycobacteria.  
 
1.3.3 Mechanism of action of D-cycloserine in mycobacteria 
The first proposal that D-alanine:D-alanine ligase was the target for D-cycloserine in M. 
tuberculosis was a study that isolated strains resistant to D-cycloserine and evaluated their uptake 
of alanine (David, 1971). The D-cycloserine resistant mutant strains were categorised as being 
either alanine permease competent or defective by measuring their uptake of D-alanine and other 
amino acids. The authors found D-cycloserine resistance mutants with normal uptake of D-alanine 
and hypothesised that these strains might harbour mutations in the ddl gene which encodes D-
alanine:D-alanine ligase. However, there was no molecular confirmation to support the 
hypothesis (David, 1971).  
 
The first formal genetic analysis of alr (gene which encodes alanine racemase) was conducted by 
Caceres et al., (1997). The authors constructed a genomic library from a D-cycloserine resistant 
mutant of M. smegmatis which was transformed back into wild-type M. smegmatis. The clones, 
which were resistant to D-cycloserine, were selected and isolated for downstream analysis. In 
their experiments, D-cycloserine resistant mutants were observed to carry a mutation in the 
promoter region of alr, which subsequently causes its overexpression. The D-cycloserine resistant 
phenotype was also confirmed in M. intracellulare and M. bovis BCG by overexpressing the M.  
smegmatis alrA gene suggesting that this mechanism of resistance could also occur in slow-
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growing and pathogenic mycobacterial species. They suggested that this was evidence indicating 
that alrA was the target for D-cycloserine, due to target amplification and less competitive 
inhibition by D-cycloserine (Caceres et al., 1997). However, if the target for D-cycloserine is 
actually ddlA then it is possible that increasing the D-alanine pool might overcome competitive 
inhibition at the second stage of the D-alanine branch pathway.  
 
Further work on the characterization of mycobacterial alr was conducted in M. smegmatis. In a 
study where the alr gene was insertionally inactivated by homologous recombination, it was 
observed even in the absence of D-alanine,  that alr was not necessary for growth (Chacon et al., 
2002).  The authors concluded that there could be an alternate pathway for D-alanine synthesis. 
However, in a subsequent study to re-evaluate if an alr knock-out could grow in the absence of 
D-alanine, the alr gene was knocked out and replaced with a kanamycin resistant cassette. Mutant 
colonies were grown in the presence and absence of D and L-alanine. The authors observed strains 
lacking the alr gene did in fact require D-alanine for growth in both Luria-Bertani medium and 
7H11 minimal medium. This indicated  that alr is essential for obtaining D-alanine for cell wall 
synthesis,  compatible with it being the target for D-cycloserine (Milligan et al., 2007). This is 
indicative that insertional inactivation of the alr gene utilised by Chacon et al., (2002) may not 
have eliminated all alanine racemase activity completely. Studies have shown that insertional 
inactivation can in some cases permit continued production of the active protein (Iredale, 1999, 
Vanhaesebroeck et al., 2004).  
 
The role of alanine racemase was further investigated in macrophages of mice using M. 
tuberculosis H37Rv (Awasthy et al., 2012). The alr gene was inactivated using a two-step 
homologous recombination technique and tested in vivo and in vitro. In vitro growth assays 
showed that the alr knockout requires low concentrations of D-alanine for growth and removal 
of this amino acid resulted in no visible growth. In the macrophage model, the alr mutant 
exhibited poor growth relative to the wild-type illustrating the need for D-alanine for survival 
intracellularly. They went on further to infect mice intravenously with the wild-type H37Rv and 
the alr mutant. After a week of infection, mice were sacrificed and organs were plated for colony 
forming units (CFU). Once inside the mice M. tuberculosis strains lacked available D-alanine, 
which resulted in the alr mutant initially losing viability and thereafter stabilizing. This suggested 
that a lack or depletion of this amino acid makes cells more susceptible to D-cycloserine. The 




To explore the relative roles of alanine racemase and D-alanine:D-alanine ligase in resistance to 
D-cycloserine a subsequent study showed that overexpression of the ddl gene from either M. 
smegmatis or M. tuberculosis could cause resistance to D-cycloserine in M. smegmatis raising the 
possibility that the D-alanine:D-alanine ligase could also be the target (Feng and Barletta, 2003). 
This was supported by the observation that a strain overexpressing both the alr and ddl genes 
displayed a higher level of resistance to D-cycloserine than strains overexpressing either gene 
alone. Belanger et al. (2000) engineered a temperature -sensitive mutant of M. smegmatis which 
was composed of a single amino acid substitution in D-alanine:D-alanine ligase (Belanger et al., 
2000).  The authors found the mutant strain to be more susceptible to D-cycloserine due to the 
decreased activity of the mutated D-alanine:D-alanine ligase enzyme further supporting the ligase 
as a target.  
 
More recent metabolomic studies have suggested that D-alanine:D-alanine ligase is in fact the 
principal target for D-cycloserine (Prosser and de Carvalho, 2013). Using [2H] isotopically 
labelled L-alanine and a mass spectrometry approach the authors tracked alanine racemase and 
D-alanine:D-alanine ligase activity in M. tuberculosis treated with D-cycloserine in order to 
determine the mechanism of action. It was found that D-alanine:D-alanine ligase was more 
inhibited indicative of D-alanine:D-alanine ligase as a target of D-cycloserine (Prosser and de 
Carvalho, 2013).  
 
Halouska et al.,(2013) aimed to identify the target of D-cycloserine by incorporating 
metabolomics and Nuclear Magnetic Resonance (NMR). They grew M. tuberculosis H37Rv and 
M. smegmatis mc2 155 cultures in media supplemented with 13C labelled alanine. The cultures 
were treated with D-cycloserine and the metabolome was extracted. The authors applied NMR to 
characterize the metabolome of  M. tuberculosis H37Rv and M. smegmatis mc2 155 cultures 
(Halouska et al., 2013). They utilised D-alanine production as a readout and found an 
accumulation of this amino acid. The authors proposed that this may be as a result of the inhibition 
of D-alanine:D-alanine ligase by D-cycloserine. They concluded that D-alanine:D-alanine ligase 
is the principal target of D-cycloserine as cell growth is suppressed when the production of D-







1.4 Mechanism of Resistance to D-cycloserine 
Resistance to D-cycloserine occurred as early as the 1950s (Steenken and Wolinsky, 1956, 
Bottero et al., 1958, Cohen and Dross, 1960, Grosset and Canetti, 1962). Strains resistant to D-
cycloserine were first observed in M. tuberculosis in 1956 (Cummings, 1956). Cummings et 
al.,(1956) showed 36% of patients receiving D-cycloserine therapy for six months developed 
resistance.  Another early key finding was that resistant mutants selected in vitro had a range of 
MICs suggesting multiple mechanisms of resistance (Nitti and Tsukamura, 1957, Tsukamura et 
al., 1963). Despite these early phenotypic observations, the genetic mechanisms of resistance in 
clinical isolates has not been defined.  
 
1.4.1 cycA 
Like resistance to other drugs, D-cycloserine resistance occurs in steps with an additional level of 
resistance. Isolation and classification of step-wise D-cycloserine resistant mutants have been 
performed in numerous bacterial species, including S. aureus (Howe et al., 1964), E. coli (Curtiss 
et al., 1965), Streptococcus gordonii (Reitz et al., 1967) and mycobacteria (Caceres et al., 1997, 
David, 1971). 
 
Further genetic studies characterised cycA, which encodes a permease (Curtiss et al., 1965) that 
transports the amino acids β-/L-/D-alanine, glycine and D-serine as well as D-cycloserine. These 
studies led researchers to investigate cycA in mycobacteria. Mycobacterium bovis bacillus 
Calmette-Guérin (BCG), which originated from the infectious M. bovis, is used as a vaccine 
against TB (Brosch et al., 2007). BCG is innately resistant to D-cycloserine (Goh and Rastogi, 
1991, Pelayo et al., 2009) and has a mutation in cycA relative to M. bovis. By complementing 
BCG with wild-type cycA they were able to partially restore susceptibility to D-cycloserine, 
suggesting cycA was also a D-cycloserine transporter in mycobacteria. But other mechanisms of 
resistance may also contribute to the D-cycloserine phenotype in BCG (Chen et al., 2012).  
 
1.4.2 Alanine racemase and the D-alanine:D-alanine ligase 
The studies described above would suggest that promoter or regulatory mutations that result in 
the upregulation of alr and ddlA genes result in resistance to D-cycloserine. Conceivable 
intragenic mutations in either or both of these genes could lead to a loss of affinity of D-




Due to the limited data available for clinical strains, of interest was a WGS study conducted on 
patient isolates. Here, the authors found in one particular patient the acquisition of the mutation 
S22L, a nonsynonymous mutation in the gene alr which was predicted to confer resistance to D-
cycloserine (Merker et al., 2013).  
 
1.4.3 Other mechanisms of resistance  
In addition to cycA, alr and ddlA there may be other mechanisms of D-cycloserine resistance. 
Peteroy et al.,(2000) constructed a laboratory mutant resistant to both D-cycloserine and 
vancomycin of M. smegmatis (Peteroy et al., 2000). In pathogenic bacterial organisms resistance 
to D-cycloserine and vancomycin resistance is normally associated with D-alanine:D-alanine 
ligase which is encoded for by the ddlA gene (Van Heijenoort, 1996).  The authors were unable 
to find mutations associated with this phenotype, including characterization of ddl, and the 
mechanism of resistance in their mutant model remains unknown. Work from other bacteria 
indicate that resistance to D-cycloserine may be more complex, and mutations in d-amino acid 
dehydrogenase (DadA) can cause resistance in E. coli (Baisa et al., 2013).  
 
1.5 L-alanine dehydrogenase  
L-alanine dehydrogenase was initially discovered in Bacillus subtilis (Wiame and Pierard, 1955). 
Rv2780 encodes L-alanine dehydrogenase (ald), which catalyzes the NAD-dependent 
interconversion between L-alanine and pyruvate. The forward reaction is necessary for aerobic 
utilization of alanine as a nitrogen source and the reverse reaction is involved in the reductive 
amination of pyruvate to L-alanine (Feng et al., 2002).  The forward and reverse reaction of L-
alanine dehydrogenase are as follows:  
 
  
1.5.1 Significance of L-alanine dehydrogenase in pathogenesis 
Alanine dehydrogenase activity  has proven to be important in some bacteria as it has been 
associated with persistence models such as sporulation.  
 
Bacillus subtilis has the ability to differentiate into heat-resistant spores under environmentally 
stressed conditions (Siranosian et al., 1993). This study revealed alanine is required for normal 
spore formation, and alanine dehydrogenase plays an essential role in growth when alanine is the 
sole carbon source, as alanine dehydrogenase is required for the catalytic deamination of alanine 
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to pyruvate and ammonia. The authors observed the ald gene is essential for normal sporulation, 
as the ald mutants showed a defectiveness in sporulation, and that pyruvate supplementation 
partially abrogated the phenotype suggesting that pyruvate generated by alanine dehydrogenase 
is an essential metabolic substrate under certain conditions (Siranosian et al., 1993).  
 
Myxococcus xanthus, is a gram-negative bacterium which is able to produce myxospores under 
starvation conditions (Bretscher and Kaiser, 1978).  This study confirmed that the aldA gene does 
encode a functional alanine dehydrogenase, which again is essential for the catalytic 
interconversion of alanine to pyruvate and ammonia. The ald mutants displayed reduced rates of 
sporulation, indicating ald is required for normal development (Ward et al., 2000).  
 
In mycobacteria, the L-alanine dehydrogenase enzyme was found to be present in infectious M. 
tuberculosis strains and absent in the vaccine strains of BCG (Andersen et al., 1992).  Chen et 
al.,(2003) showed BCG strains were unable to utilise L-alanine or D-alanine as a sole nitrogen 
source due to a frameshift mutation in the ald gene (Chen et al., 2003). This could be reversed by 
complementing with wild-type ald. BCG’s inability to replicate in humans has been proposed to 
be associated with the absence of a functional alanine dehydrogenase preventing the development 
of protective immunity (Scandurra et al., 2006). In M. bovis the ald gene possesses a single 
nucleotide deletion and consequently lacks alanine dehydrogenase (Chen et al., 2003). These 
studies demonstrated that there are differences in the central metabolism between M. bovis and 
M. tuberculosis (Chavadi et al., 2009). Regardless of changes in metabolism, M. bovis can cause 
disease in humans and BCG complemented with the M. tuberculosis ald gene displayed no change 
in survival in both macrophages and mice (Scandurra et al., 2006).  
 
Mycobacterium marinum is the causative agent of fish and amphibian TB (Aronson, 1926, Clark 
and Shepard, 1963). Gene expression profiling of M. marinum, used as a surrogate to study the 
pathogenicity of M. tuberculosis  in its persistence state in granulomas, found that ald was one of 
the genes upregulated in frog granulomas upon nutrient starvation (Chan et al., 2002). This 
indicates that ald may be important in maintaining the NAD pools under stressful conditions, or 
could be involved in persistence (Ramakrishnan et al., 2000, Chan et al., 2002).  
 
In Mycobacterium smegmatis L-alanine dehydrogenase activity was increased during oxygen 
depleted conditions (Dick et al., 1998, Hutter and Dick, 1998, Raynaud et al., 1998, Usha et al., 
2002). This has led to the belief that L-alanine dehydrogenase may be involved in the recycling 
of NADH under respiratory-inhibitory conditions such as hypoxia (Hutter and Dick, 1998). This 
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study also showed alanine dehydrogenase was overproduced under anaerobic conditions, which 
mimic dormancy (Hutter and Dick, 1998). Feng et al., (2002), further illustrating that L-alanine 
dehydrogenase may play an essential role in oxygen limited environments (Feng et al., 2002).  
 
In a study conducted on M. tuberculosis, ald was found to be upregulated under hypoxic 
conditions (Giffin et al., 2012). Here, alanine dehydrogenase played a multi-specific enzymatic 
role where it was able to utilize both glyoxylate or pyruvate as substrates. In a subsequent study, 
alanine dehydrogenase was found to be highly expressed in the late non-replicating persistent 
(NRP-2) stage (Giffin et al., 2016). They also reported a growth defect in strains which possessed 
the alanine dehydrogenase mutant. This study in M. tuberculosis showed that ald had a role in 
reaeration of hypoxic cultures. 
 
1.6 Problem statement 
The emergence of drug-resistant M. tuberculosis poses a huge threat to TB control strategies. To 
overcome this significant problem, there is need for the development of novel rapid diagnostics 
for the detection and identification of drug-resistant M. tuberculosis. Similarly, the identification 
of genes and mechanisms which may confer drug resistance in M. tuberculosis are urgently 
required to stem this global epidemic.  
 
1.7 Rationale 
To date little is known regarding the mechanism of resistance of D-cycloserine among M. 
tuberculosis clinical strains. By utilizing WGS we would be able to identify novel drug resistance 
conferring mutations, which could elucidate new mechanisms leading to D-cycloserine resistance. 
We incorporated the use of ald’s LOF in housekeeping and clinical M. tuberculosis strains to 
demonstrate D-cycloserine resistance in vitro. 
 
1.8 Hypothesis 
L-alanine dehydrogenase (ald) is involved in the alanine metabolism pathway. Genomic 
association studies identified LOF mutations in ald restricted to drug-resistant strains. We 





To determine the functional consequences of ald’s LOF and their effect on D-cycloserine 
susceptibility.  
1.10 Specific Objectives 
1. To characterise novel LOF mutations identified by genomic studies to determine their 
effect on drug susceptibility. 
 
2. To perform DST’s to first and second-line TB drugs on single gene knock-outs to identify 
genes that confer drug resistance. 
 
3. To compare growth and viability of the sequenced clinical isolates under selective drug 
exposure. 
 
4. To assess if loss of ald function confers increased cycloserine resistance as evidenced by 
longer TTP in Mycobacterial Growth Indicator Tubes (MGIT) supplemented with D-
cycloserine. 
 




Materials and Methods 
 
2.1 Study design 
2.1.1 Study Population 
Samples for this study were obtained retrospectively and prospectively from individuals during 
2008-2013 (based in Kwazulu-Natal, South Africa). Full ethical approval was obtained from the 
University of KwaZulu-Natal following protocols Ref:  
 
EXP052/06- Rapid survey of drug-resistant tuberculosis in Kwazulu-Natal,  
BF005/09- Treatment outcomes of Extensively Drug-Resistant (XDR-TB) at King George V 
Hospital, Kwazulu-Natal, South Africa 
BE075/12- New diagnostics for TB Drug-Susceptibility Testing (TB-DST) 
BE085/12- Analysis of any microbiological data generated from the laboratory, including 
bacteria, mycobacteria, fungi and parasites for publication purposes 
and BE022/13- Collection of Sputum, Urine and Blood samples for research at K-RITH 
 
Expedited ethical approval was obtained from the University of KwaZulu-Natal following 
protocol Ref:  
 
BE482/16- Genetic mechanisms of D-cycloserine resistance 
 
2.2 Procedures 
2.2.1 DNA extraction 
Isolation of genomic DNA using the cetyltrimethylammonium bromide (CTAB)-lysozyme 
method is one of the most efficient methods of extraction (Larsen et al., 2007a). This method 
yields high quality DNA which is useful for Southern blotting, PCR and the screening of clones 
(Connell, 1994). The CTAB-lysozyme method is suitable for isolation of DNA from small volume 
cultures (Larsen et al., 2007a).  
 
2.2.1.1 Growth conditions of clinical strains prior to extraction 
Clinical isolates were streaked on Middlebrook 7H10 agar medium. A single colony was picked 
for growth in Middlebrook 7H9 liquid medium supplemented with 0.5% glycerol, 0.05% Tween 
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80 and 10% oleic acid-albumin-dextrose-catalase (OADC) at 37C with 5% CO2 (Larsen et al., 
2007b). DNA was extracted from the liquid culture using the (Larsen et al., 2007a) protocol.  
 
2.2.1.2 Extraction of genomic DNA (Larsen et al., 2007a) 
Procedure 
Day 1 
1. Preceding DNA extraction, 1 mL of 10% glycine was added to 10 mL late log culture. The 
samples were vortexed briefly and incubated at 37C with a CO2 content of ~5 % for 24 hours.  
 
Day 2 
2. Samples were removed from the incubator and transferred to individually labelled 50 mL 
conical tubes. Centrifugation followed at 2000 x g for 10 minutes.  
3. The supernatant was discarded and samples were resuspended in 450 µL GTE solution. 
Samples were then transferred to individual microcentrifuge tubes holding 50 µL of a freshly 
prepared 10 mg/mL lysozyme solution. 
 
Day 3 
4. The samples were further incubated at 37C, 5% CO2 for 24 hours. 
5. A 2:1 solution of 10% SDS and 10 mg/mL proteinase K was prepared. A volume of 150 µL 
of this freshly prepared solution was added to the samples and were mixed gently. The 
samples were incubated for a period of 30 minutes on a heating block at 55C.   
6. A 200 µL aliquot of NaCl was added to each sample tube and mixed gently.  
7. CTAB solution was preheated to 65C. A volume of 160 µL of this reagent was added to each 
sample tube. Samples were further incubated for 10 minutes at 65C.  
8. Following heating, ~1 mL of 24:1 (v/v) chloroform/isoamyl was added to the sample tubes. 
The tubes were shaken vigorously.  
9. Tubes were centrifuged at 7000 x g for 5 minutes. 
10. The aqueous supernatant (900 µL) was then transferred to a new microcentrifuge and 
~900 µL of 24:1 (v/v) chloroform/isoamyl was added and the extraction process repeated. 
11. Following centrifugation, the aqueous supernatant (~800 µL) was transferred to a new 
microcentrifuge tube.  
12. To the supernatant 560 µL of isopropanol was added. Samples were mixed by inversion to 
precipitate the DNA. 
13. Samples were incubated at room temperature for 10 minutes. 
14. Following incubation samples were microcentrifuged at 7000 x g for 10 minutes.  
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15. The supernatant was then discarded and the pellet was washed with 1 mL of 70% ethanol. 
16. Samples were again microcentrifuged at 7000 x g for 10 minutes. 
17. The supernatant was discarded post ethanol wash and the pellets were allowed to air-dry for 
15 minutes. 
18. To the pellet 50 µL of TE buffer was added to elute the DNA.  A 24-hour incubation in the 
4C refrigerator followed to dissolve the DNA.  
19. Samples were then stored at 20C for downstream applications.  
 
2.2.2 Drug susceptibility testing (DST)  
DST is critical in prescribing an effective drug regimen for appropriate patient care (Woods, 
2000). Testing is traditionally conducted on cultured M. tuberculosis isolates from patients 
(Woods, 2000). Phenotypic testing involves culturing of patient isolates in the presence of TB 
drugs to determine resistance and susceptibility profiles (Sirgel et al., 2009).  
 
2.2.2.1 Growth conditions for DST (Larsen et al., 2007b) 
M. tuberculosis strains of interest were cultivated in Middlebrook 7H9 liquid medium 
supplemented with 0.5% glycerol, 0.05% Tween 80 and 10% OADC at 37C with 5% CO2.  
Strains were grown to an optical density at 600 nm (OD600) of 0.3 to 0.8. Cultures were diluted to 
a starting inoculum of 1x 103 CFU/mL for downstream testing. The initial inoculum was 
confirmed by plating onto 7H10 Middlebrook solid agar medium. Fresh cultures were used as 
older cultures may result in unreliable DST results. Cultures were grown from a glycerol stock 
and passaged once before DST set up.  
 
2.2.2.2 Agar proportion method (Canetti et al., 1963, Canetti et al., 1969, Kent and Kubica, 1985) 
DST was performed on 7H11 Middlebrook agar medium supplemented with OADC. Strains were 
tested on control and anti-tubercular media.  The following drugs were tested at the WHO 
recommended critical concentrations i.e. isoniazid 0.1 µg/mL, isoniazid 1.0 µg/mL, rifampicin 
1.0 µg/mL, ethambutol 7.5 µg/mL, streptomycin 2.0 µg/mL, ofloxacin 2.0 µg/mL and kanamycin 
6.0 µg/mL. The critical concentration is defined as the amount of drug in the medium that prevents 
the growth of sensitive bacteria but not that of resistant mutants (WHO, 2008b). 
 
When conducting the agar proportion method, resistance of a strain is established at the 1% level. 
A strain is considered resistant if 1% or more of the bacterial population is resistant to a specified 
drug. The tested cultures were incubated for 3-4 weeks. The percentage of the colonies on the 




1. Strains grown on 7H10 agar medium were used as the source of inoculum. 
2. Colonies were picked and homogenized with 3mm diameter sterile glass beads. 
3. Samples were vortexed for approximately 20 seconds and the suspension adjusted to equate 
a McFarland standard 1.  
4. Cultures were diluted ten-fold (0.5 mL of bacterial suspension diluted in 4.5 mL in sterile 
distilled water) 
5. A volume of 100 µL of each dilution was inoculated onto each quadrant plate.  
6. Plates were incubated at 37 ºC in the presence of 5% CO2 for 3-4 weeks.  
7. Result interpretation was done by comparing growth on control media and media containing 
drug. If more than 1 % of the test population was observed on the drug containing media, the 
result was interpreted as resistant to that drug.  
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2.2.3 ald complementation of CDC1551 knock-out and M. bovis BCG Danish 1331 
2.2.3.1 PCR amplification of ald from H37Rv 
All PCR reagents were kept on ice to prevent degradation. The Δald of M. tuberculosis (JHU2780-
209) was obtained from the Tuberculosis Animal Research and Gene Evaluation Taskforce 
(TARGET) mutant library (http://webhost.nts.jhu.edu/target/). 
 
A 1.116 kb fragment spanning the ald gene region was PCR amplified from M. tuberculosis 
(H37Rv) genomic DNA using primers from Integrated DNA Technologies (IDT) containing the 
NotI and PciI restriction sites.  
 
Primer set KM_P27 (5’AAATTTGCGGCCGCATGCGCGTCGGTATTCCGACCG 3’) and  
KM_P28 (5’GGTGGTACATGTTCAGGCCAGCACGCTGGCG 3’) was used.  
 
Procedure 
1. In a sterile 0.2 mL microfuge tube, reagents were mixed in the following order: 
 
Table 2.1 Reagents used in PCR amplification of ald from H37Rv 
Reagents Amount (µL) 
Nuclease free water 4  
Buffer(2x) 12.5  
Template DNA 0.25  
dNTPs mix 5  
DMSO 1.25  
Forward primer 0.75  
Reverse primer 0.75  
Taq DNA polymerase 0.5  
Total  25  
 
2. The KOD Xtreme TM Hot Start DNA Polymerase kit was used (Merck Millipore, Cat. 
No:71975-3). The PCR reaction mix contained 1 x PCR buffer, 0.3 μM KM_P27 forward 
primer, 0.3 μM KM_P28 reverse primer, 0.4 mM dNTP mix, 0.5 U Taq polymerase, 5% 
DMSO and 0.025 ng total DNA.  
3. All reagents were mixed gently by vortex and briefly centrifuged to collect all components to 
the bottom at the tube. 
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4. Amplification reactions consisted of an initial denaturation step of 2 minutes at 94°C, 
followed by 35 cycles of 15 seconds at 98°C, 30 seconds at 60°C, and 70 seconds at 68°C, 
and a final extension step of 5 minutes at 68°C. A final holding step was set at 4 °C.  
5. PCR products were run on a 0.9% agarose gel at 150 V, 400 mA for 30 minutes with the 
correct size product excised.  
 
2.2.3.2 Gel Purification of PCR product 
This procedure was conducted in accordance with the protocol in the QIAquick® Gel Extraction 




1. A 450 µL aliquot of Buffer QG was added to a micro-centrifuge tube containing a 150mg gel 
slice.  A yellow colour of the Buffer QG is indicative of a relatively neutral pH (≤7.5).  
2. This was followed by the addition of 150 µL 100% isopropanol to each sample tube and 
mixed gently. 
3. A QIAquick spin column was then placed in a 2 mL collection tube. The sample was applied 
to the QIAquick column and centrifuged for 1 minute. In this way, DNA binding to the 
column took place.  
4. The flow-through was discarded and the QIAquick column was inserted a collection tube.  
5. An aliquot of 750 µL of Buffer PE was added to the column and centrifuged at 15000 x g for 
one minute.  
6. The flow through was discarded. The column was centrifuged once more in the 2 mL 
collection tube for one minute at 15000 x g to eliminate remaining wash buffer.  
7. The QIAquick column was placed into a sterile 1.5 mL microcentrifuge tube. Fifty microliters 
of nuclease free water (Qiagen.: Cat no 129114), was added to the middle of the QIAquick 
membrane to elute the DNA.  
8. The column was allowed to stand for two minutes to increase the yield of purified DNA and 
thereafter centrifuged for two minutes. The product was stored at -20°C until further use. 
 
2.2.3.3 Digestion of backbone vector and of PCR product 
The backbone vector AYp240 contained an Emerald fluorescent protein expressed off the 
mycobacterial optimized promoter (MOP) (George et al., 1995) in a modified L5_integrating 
mycobacterial expression vector. PciI and NotI restriction sites were used to digest the chosen 
vector to remove the Emerald fluorescent protein as well as to digest the PCR amplified product, 
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to facilitate insertion of the ald gene to create the pMCZ-MOP_Rv2780 expression vector for 
complementation.  
 
Digestion conditions for backbone vector (AYp240): 
Table 2.2 Reagents used in digestion reaction of the backbone vector (AYp240) 
Reagents Amount (µL) 
Template DNA 39.53  
Buffer 5  
BSA 0.5  
PciI 2.5  
NotI -HF       2.0  
dH20 0.47  
Total  50  
 
 
Digestion conditions for PCR product (ald): 
Table 2.3 Reagents used in digestion reaction of the PCR product (ald) 
Reagents Amount (µL) 
Template DNA 22.67  
Buffer 5  
BSA 0.5  
PciI 2.5  
NotI -HF       2.0  
dH20 17.33  





2.2.3.4 Gel Purification of backbone vector and PCR product 
This procedure was performed as explained in section 2.2.4.2 using the QIAquick® Gel 
Extraction Kit (Cat. No.:28706). 
 
Procedure 
1. The gel purified products were run on a 0.9% agarose gel at 150 V, 400 mA for 30 minutes.  
2. Gel images were viewed using the BIO-RAD ChemiDocTM MP Imaging System.  
 
 
Figure 2.1: Agarose gel electrophoresis of digested and purified backbone vector and ald PCR 
product. AYp240 and PCR amplified ald (Rv2780) were restriction digested using PciI and NotI. Digested 
products were purified using gel extraction. Purified digests were run on a gel to confirm digests.  
 
2.2.3.5 Ligation of ald fragment with mycobacterial expression vector  
Procedure 
1. After digestion and purification of the vector backbone and PCR product, a 5:1 molar ration 
of insert to vector was incubated for 4 hours at 22ºC to facilitate ligation of the ald to the 
vector backbone. 





Table 2.4 Reagents used in the ligation reaction of the PCR product (ald) 
 
3. The entire ligation reaction was then dialyzed using a 0.025 µm nitrocellulose membrane 
(Merck Millipore, Cat Number VSWP02500) to remove excess salts and enzymes. 
4. A 2.5 μL aliquot of the dialyzed ligation mixture was added to 50 μL in house prepared DH5 
E. coli electrocompetent cells and gently mixed by tapping lightly. All tubes were kept on 
ice.  
5. The mixture was then transferred to a 0.2cm cuvette and then electroporated in the BIO-RAD 
Gene Pulser Xcell using the following settings:  2.5 kV, 25 µF and 1000 Ω, following which 
cells were kept on ice for two minutes.  
6. The cells were recovered in 1 mL SOC medium, and incubated shaking at 37ºC for 1hour to 
allow for healing and expression of the antibiotic resistance product. 
7. Healed cells were then plated on LB agar + 50 µg/mL Zeocin and incubated at 37ºC overnight.  
 
2.2.3.6 Plasmid Mini Preparation 
This procedure was conducted in accordance with the protocol in the QIAprep® Spin Miniprep 
Kit (Qiagen, Cat. No: 27106) with slight modifications. 
 
Procedure 
1. Six colonies from transformation plates were picked and used to inoculate 5 mL LB broth + 
50 µg/mL zeocin in 15 mL centrifuge tubes, which were incubated at 37ºC overnight.  
2. A 2 mL volume of the overnight cultures were centrifuged at 12000 x g for 3 minutes to pellet 
cells.  
3. Supernatants were discarded and the pellets resuspended in 250 µL of Buffer P1 (Tris Buffer), 
and transferred to 1.5 mL microcentrifuge tubes.  
Reagents Amount (µL) 
Vector  5.1  
Insert 6.56  
Buffer 2  
Ligase 0.2  
dH20 6.14  
Total  20  
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4. A volume of 250 µL of Buffer P2 (NaOH and SDS) was added to the resuspended pellets 
containing Buffer P1 and mixed by inverting the tubes 4-6 times. A clear solution was 
observed.  
5. Thereafter, 350 µL Buffer N3 was added (acetic acid, a neutralisation agent), and the 
microcentrifuge tubes were mixed thoroughly by inverting 4-6 times, at which point, the 
solution turned turbid.   
6. Samples were then centrifuged for 10 minutes at 15000 x g. 
7. Supernatants were transferred to labelled spin columns, following which the columns were 
centrifuged for 60 seconds at 15000 x g and the flow through from the collection tubes 
discarded.  
8. Spin columns were then washed with 750 µL Buffer PE and centrifuged for 60 seconds at 
15000 x g and the flow through discarded.  
9. An additional centrifugation step was conducted for 60 seconds at 15000 x g to remove 
residual wash buffer.  
10. Spin columns were then placed in a clean 1.5 mL microcentrifuge tubes.  
11. Samples were eluted by the addition of 50 µL nuclease free water (Qiagen.: Cat no 129114) 
to the membrane of the spin columns. Tubes were allowed to stand for two minutes before 
being centrifuged for two minutes at 15000 x g to recover plasmid DNA. 
 
2.2.3.7 Confirmatory Digest and Gel Electrophoresis 
Procedure 
1. Plasmid DNA preparations were then digested using restriction enzyme SacI to confirm 
successful clones. 
2. The confirmatory digest was set up as follows: 
 
Table 2.5 Reagents used in confirmatory digestion of transformants 
Reagents Amount (µL) 









3. Digest products were run on a 0.9% agarose gel at 150V, 400mA for 30 minutes.  




Figure 2.2: SacI digest confirmation of transformant colony picks 
Gel image showing confirmatory digest of transformant colony picks for the pMCZ-MOP_Rv2780 















Figure 2.3: Schematic illustration of pMCZ-MOP_Rv2780.  Rv2780 (ald) was cloned into our L5 
integrating, zeocin-marked mycobacterial expression vector, under the control of MOP using the NotI and 




2.2.3.8 Transformation of ald into M. tuberculosis (Van Kessel and Hatfull, 2007, Parish and 
Stoker, 1998) 
A successful clone of pMCZ-MOP_Rv2780 was then transformed into CDC1551 Δald and 
M. bovis BCG Danish 1331. 
 
Procedure 
1. M. tuberculosis strain CDC1551 Δald was grown in Middlebrook 7H9 liquid medium 
containing kanamycin (50 µg/mL) supplemented with 0.5% glycerol, 0.05% Tween 80 and 
10% OADC. The M. bovis BCG Danish 1331 was grown in Middlebrook 7H9 liquid medium 
supplemented with 0.5% glycerol, 0.05% Tween 80 and 10% OADC. These strains were 
incubated at 37C with 5% CO2 to an optical density at 600 nm (OD600) of 0.6 to 0.8. 10 mL 
of starting culture was used.  
2. The culture was transferred to individually labelled 50 mL conical tubes. Centrifugation 
followed at 4000 x g for 15 minutes.  
3. The supernatant was discarded and the pellet was washed with a 5 mL volume of sterile room 
temperature 10% sterile glycerol. The cells were then centrifuged at 4000 x g for 15 minutes. 
4. Step 3 was repeated with the pellet this time being washed with a 2.5 mL volume of sterile 
room temperature 10% sterile glycerol. 
5. After centrifugation and discarding of the supernatant, the pellet was resuspended in 1/10th 
the original volume of the culture. 
6. A 400 µL volume of cells was used for each transformation. Total DNA of 100ng was mixed 
with the respective competent cells in a sterile microcentrifuge tube.  
7. The bacteria and DNA was then transferred to a 0.2cm cuvette and then electroporated using 
the Biorad Gene Pulser Xcell using the following settings:  2.5 kV, 25 µF and 1000 Ω. A 
volume of 1 mL of 7H9 containing OADC and 20% Tween 80 was added to the electroporated 
cells and then transferred to a 30 mL inkwell which was incubated shaking at 37oC overnight 
to allow for expression of antibiotic resistance. 
8. Healed cells were plated on 7H10 agar containing zeocin (20 µg/mL) for M. bovis BCG 
Danish 1331, and zeocin (20 µg/mL) and kanamycin (25µg/mL) for CDC1551 Δald, with the 





2.2.3.9 Small Scale DNA Extraction for confirmatory diagnostic PCR 
This procedure was conducted in accordance with the protocol in the Hain GenoLyse Extraction 
Kit (Cat. No.: 51610) with modifications.  
 
Procedure 
1. Two transformant colonies for each transformation were scraped off the plate and used to 
inoculate 3 mL of 7H9 liquid medium, containing zeocin (20 µg/mL) for M. bovis BCG 
Danish 1331::pMCZ-MOP_Rv2780 (hereafter referred to as BCG::ald-comp), and zeocin 
(20 µg/mL) and kanamycin (25 µg/mL) for CDC1551Δald:: pMCZ-MOP_Rv2780 (hereafter 
referred to as Δald-comp), supplemented with 0.5% glycerol, 0.05% Tween 80 and 10% 
OADC. These cultures were incubated shaking at 37oC for two weeks.  
2. An aliquot of 500 µL cells were centrifuged for 5 minutes at 15 000 x g 
3. After centrifugation the supernatant was discarded and 100 µL of Lysis Buffer (A-LYS) was 
added to the pellet and resuspended.  
4. The samples were incubated for a period of 30 minutes on a heating block at 95C.   
5. A 100 µL aliquot of Neutralization Buffer (A-NB) was added to each tube and mixed gently. 
6. The tubes were then centrifuged for 5 minutes at 15 000 x g.  
7. Following centrifugation, the supernatant was transferred to a new microcentrifuge tube, with 
a 5 µL aliquot of the supernatant used for downstream PCR.  
 
2.2.3.10 Small Scale DNA Extraction for confirmatory PCR 
PCR primers were internal to the integrated region of the plasmid, but external in relation to ald, 
to ensure PCR amplification of our exogenously inserted ald gene and not the endogenous ald 
locus.  
 
A 1.319 kb fragment spanning the MOP and ald gene was amplified from transformant colony 
picks using the ANY_P58 (5’TGGCAGTCGATCGTACGCTAGTT 3’) and ANY_P59 
(5’GAGCCTATGGAAAAACGCCAGCA 3’) primers from Integrated DNA Technologies 
(IDT). All PCR reagents were kept on ice to prevent degradation. 
 
Procedure 




Table 2.6 Reagents used in PCR amplification of exogenously inserted ald gene 
Reagents Amount (µL) 
Nuclease free water 1 
Buffer(10x) 12.5 
Template DNA 2.5 
dNTPs mix 5 
DMSO 1.25 
Forward primer 1 
Reverse primer 1 
Taq DNA polymerase 0.75 
Total 25 
 
2. The Qiagen Taq DNA Polymerase kit was used (Qiagen, Cat. No:201203. The PCR reaction 
mix contained 1 x PCR buffer, 0.4 μM ANY_P58 forward primer, 0.4 μM ANY_P59 reverse 
primer, 0.4 mM dNTP mix, 0.5 U Taq polymerase and 5% DMSO.  
3. All reagents were mixed gently by vortex and briefly centrifuged to collect all components to 
the bottom of the tube. 
4. Amplification reactions consisted of an initial denaturation step of 2 minutes at 94°C, 
followed by 35 cycles of 15 seconds at 98°C, 30 seconds at 55°C, and 90 seconds at 68°C, 
and a final extension step of 5 minutes at 68°C. A final holding step was set at 4 °C. A gel 
product of 1.319kb was confirmed by electrophoresis.  
5. The PCR products were run on a 0.9% agarose gel at 150V, 400mA for 30 minutes.  


















Figure 2.4: Confirmation of complementation of ald gene in CDC 1551 Δald and M. bovis BCG 
Gel image showing PCR amplification of a 1.319kb fragment spanning the MOP and ald gene from DNA 
obtained from Δald-comp and BCG::ald-comp transformant colony picks confirming presence of 






2.2.4 D-cycloserine growth assay assessed by Mycobacterial Growth Indicator Tube  
2.2.4.1 BD BACTEC™ MGIT™ 960 System ((Leitritz et al., 2001, Alcaide et al., 2000, Tortoli et 
al., 1999, Hanna et al., 1999) 
The BACTEC™ MGIT™ 960 System is an automated system which utilizes a fluorescent 
indicator i.e. an oxygen-quenched fluorochrome, tris 4, 7-diphenyl-1, 10-phenonthroline 
ruthenium chloride pentahydrate, which is able to detect oxygen depletion due to bacterial growth. 
As oxygen is used, the fluorochrome is no longer inhibited and results in fluorescence within the 
MGITs. 
 
The system accommodates MGITs which are incubated at 37C. The tubes are scanned into the 
system by a barcode, the machine scans the MGITs every hour for increased fluorescence.  Viable 
organisms utilize the oxygen and thus produce a fluorescent signal, indicating positivity. A tube 
is considered instrument negative if they remain in the machine for a period of 42-56 days with 
no signs of growth/positivity. TTP is recorded in days and hours. 
 
The MGIT medium consists of 7 mL modified Middlebrook 7H9 broth base medium that supports 
faster growth of mycobacteria. MGIT OADC (Oleic acid, Albumin, Dextrose and Catalase) or 
MGIT 960 Growth Supplement is further added to the medium to support the growth of M. 
tuberculosis complex.  
  
2.2.4.2 MGIT Preparation (see Appendix 1) 
2.2.4.3 Antibiotic preparation (see Appendix 1) 
The MGIT tubes were added with and without D-cycloserine to achieve final concentrations of 
0, 7.5 µg/mL, 15 µg/mL and 30 µg/mL. MGITs were set up in triplicate. A drug control for each 
concentration of D-cycloserine was set up as a negative control. 
 
2.2.4.4 Growth conditions for MGIT growth inhibition assay and set up (Larsen et al., 2007b) 
M. tuberculosis strains of interest were cultivated in Middlebrook 7H9 liquid medium 
supplemented with 0.5% glycerol, 0.05% Tween 80 and 10% OADC at 37C with 5% CO2 with 
agitation at 37C. Strains were grown to an optical density at 600 nm (OD600) of 0.3 to 0.8. 
Cultures were diluted to a starting inocula of 1x 103 CFU/mL for downstream testing. The initial 
inoculum was confirmed by plating onto 7H10 Middlebrook solid agar medium. Fresh cultures 
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were used as older cultures could result in unreliable results. Cultures were grown from a glycerol 
stock and passaged once before assay set up.  
Procedure  
1. Growth of cultures was monitored by measuring the OD600.  
2. If strains were at their desired OD i.e. ~ 0.3-0.8, they were diluted to 1x 103 CFU/mL in 50 mL 
conical tubes.  
3. The diluted cultures were vortexed and 500 μL was added into each MGIT tube for each 
concentration in triplicate. 
4. Dilutions of the starting inoculum were plated onto 7H10 Middlebrook solid agar medium to 
determine the CFU of the initial inoculum.  
5. After inoculation, each MGIT was scanned into the BACTEC™ MGIT™ 960 System.  
6. Tubes remained in the system until positive for growth. Once flagged positive, the TTP for 
each tube was recorded.  
 
2.2.5 D-cycloserine minimum inhibitory concentration (MIC) determination on Löwenstein–
Jensen (LJ) 
Löwenstein–Jensen (LJ) is a selective egg-based medium used to culture Mycobacterium species 
for decades (Canetti et al., 1963). LJ slants incorporates inspissated eggs, malachite green and 
glycerol to promote the growth of mycobacteria (Canetti et al., 1969). D-cycloserine drug 
susceptibility has only been validated on LJ medium and is not performed routinely due to 
instability associated with the drug (Woods, 2000, Kam et al., 2010).  
 
2.2.5.1 Antibiotic preparation (see Appendix 1) 
2.2.5.2 LJ medium preparation (see Appendix 1) 
2.2.5.3 Growth conditions for LJ MIC determination of D-cycloserine and assay set up (Larsen 
et al., 2007b) 
M. tuberculosis strains of interest were cultivated in Middlebrook 7H9 liquid medium 
supplemented with 0.5% glycerol, 0.05% Tween 80 and 10% OADC at 37C with 5% CO2.  
Strains were grown to an optical density at 600 nm (OD600) of 0.3 to 0.8. Cultures were diluted to 
a starting inocula of 1x 103 CFU/mL for downstream testing. The initial inoculum was confirmed 
by plating onto 7H10 Middlebrook solid agar medium. Fresh cultures were used as older cultures 
may result in unreliable results. Cultures were grown from a glycerol stock and passaged once 




1. Growth of cultures was monitored by measuring the OD600.  
2. The strains were diluted to 1x 103 CFU/mL in 50 mL conical tubes.  
3. The diluted cultures were vortexed and 100 μL was added into each LJ slopes for each 
concentration in duplicate. 
4. Dilutions of the starting inoculum were plated onto 7H10 Middlebrook solid agar medium to 
determine the CFU of the initial inoculum.  
5. The inoculated LJ slopes were incubated at 37°C with 5% CO2 for 4 weeks. 
6. Result interpretation of the LJ slopes were done after 4 weeks to report the MIC for each 
tested strain. MIC is defined has the lowest drug concentration, which inhibits 90% of the 
bacterial population when compared to the no drug control (Sirgel et al., 2009, Angeby et al., 
2012).  
 
2.2.6 Statistical tests 
Statistical analysis and graphical representation of graphs were done on Graph Pad Prism (version 
6.0). Statistical tests used in the analysis were the Two-Way ANOVA, to compare across groups. 
A p value <0.05 was considered significant. The Mann-Whitney U test was used for pairwise 







3.1 Population based WGS of M. tuberculosis clinical isolates 
We assembled a collection of drug susceptible and drug-resistant clinical isolates that were 
collected retrospectively and prospectively from individuals during 2008-2013 in Kwazulu-Natal, 
South Africa (Table 3.1). We selected isolates from different studies to have a population based 
sample that was enriched for drug resistance isolates and reflected the antecedents of current 
circulating strains. 
 
The KwaZulu-Natal Drug Surveillance Study was a multicentre study conducted to determine the 
incidence of drug-resistant TB across KwaZulu-Natal, included susceptible isolates, and provided 
samples that represented the diversity of strains circulating in the province. The PROX, CUBS 
and NHLS studies were prospective studies of patients with MDR and XDR-TB, and allowed us 
to enrich for strains with multiple second-line resistances. The Phage study was also a 
contemporary prospective study that allowed us to access drug susceptible isolates. We also 
included three historical isolates (KZN4207, KZN1435, KZN605) that had been previously 
sequenced (Koenig, 2007, Ioerger et al., 2009).  
 
For genotypic-phenotypic studies it is important to eliminate the potential confounding effects of 
mixed infection. We therefore streaked isolates from glycerol stocks onto 7H10 agar medium and 
picked single colonies for sub-culture for the majority of these strains. DNA was extracted using 
conventional CTAB methodology (Larsen et al., 2007a). WGS and analysis of these strains was 




Table 3.1: Description of study cohorts (Cohen et al., 2015) 
Cohort Name 
 
Cohort Description Collection Strategy and 




Cross-sectional study of 
outpatients and inpatients 
hospitalised with a cough. 
Samples were collected from 
each district in KwaZulu-Natal 
Retrospective, 2008– 
2010 
Prospective Collection of 
Extensively Drug- 
Resistant TB (PROX) 
Prospective study of patients 
newly 
commencing XDR treatment at 




Phage Study Patients newly diagnosed with 
pulmonary 
TB at  
Prince Cyril Zulu clinic in 
central Durban. These samples 
were collected before the start 
of treatment 
Prospective, 2013 
National Health Services 
Laboratory (NHLS) 
Collection of drug-resistant 
clinical isolates 
sent for DST at the central 
NHLS TB Laboratory 
Prospective, 2013 
Collection of Urine Blood 
Sputum Study (CUBS) 
Prospective collection of 
patients newly 
initiating MDR or XDR 











3.2 Identification of loss-of-function mutations associated with resistance. 
To identify mutations associated with resistance our sequences of clinical isolates from KwaZulu-
Natal were combined with a dataset of 161 sequenced strains from China. Whole genome 
association analysis to identify drug resistance conferring mutations in M. tuberculosis is 
problematic. The accumulation of mutations occurs in a stepwise fashion, with resistance to first-
line drugs usually preceding second-line and third-line resistance. As a result, mutations known 
to cause resistance to first-line drugs are often associated with second-line phenotypic resistance 
when association analysis are done. In addition, drug resistance is transmitted and clonal 
expansion of drug-resistant strains has amplified resistance in our setting (Cohen et al., 2015). 
Genetic drift can also occur during clonal expansion and non-resistance conferring mutations can 
therefore be erroneously associated with resistance. To overcome this, analysis at the BROAD 
Institute combined a measure of convergent evolution with the strength of association to 
overcome these problems. In addition, multiple mutations in single genes were collapsed to form 
a single variant, which increase power to detect rarely occurring variants. This analysis was then 
applied to strains only with unexplained resistance. The details of this analysis are beyond the 
scope of this Master thesis and have been described elsewhere (Desjardins et al., 2016).  
 
We chose to concentrate on LOF mutations. These mutations included insertions or deletions 
(INDELS), frameshift mutations and stop codons. Unlike SNPs whose effects on protein function 
are hard to predict bioinformatically, LOF mutations will definitely cause inactivation of proteins. 
By focussing on LOF mutations we reasoned that we would have a greater chance of identifying 
mutations that have phenotypic consequences. From the association analysis, we therefore 
identified 21 genes (Table 3.2) with LOF mutations, from strains with unexplained drug 












Table 3.2: Genes with loss-of-function associated with phenotypic resistance 
List of genes with LOF mutations that were associated with resistance in M. tuberculosis. Gene 








Rv0157 pntB NAD(P) subunit and functions as a proton pump across the membrane 
 
Rv0205  A membrane protein. May play a role in cell wall and cell wall 
processes 
 
Rv0242c fabG4 3-oxoacyl- [acyl-carrier protein] which is involved in the fatty acid 
biosynthesis pathway 
Rv0552  hypothetical protein with unknown function 
 
Rv0554 bpoC hypothetically involved in detoxification reactions 
 
Rv0579  hypothetical protein with unknown function 
 
Rv0779c  transmembrane protein with unknown function 
 
Rv1157c  alanine and proline rich protein with unknown function 
 
Rv1187 rocA Involved in the arginase pathway 
 
Rv1250  Potential transport of drug across the membrane 
 
Rv1277  hypothetical protein with unknown function 
 
Rv1375  hypothetical protein with unknown function 
 
Rv1975  hypothetical protein with unknown function 
 
Rv2042c  hypothetical protein with unknown function 
 
Rv2088 pknJ Involved in signal transduction (via phosphorylation) 
 
Rv2780 ald May play a role in cell wall synthesis as L-alanine is an important 
constituent of the peptidoglycan layer 
 
Rv3197A whiB7 Involved in transcriptional regulation 
 
Rv3436c glmS catalyzes the first step in hexosamine metabolism 
 
Rv3448 eccD4 ESX-4 secretion system protein with unknown function 
 




mmpL8 A membrane transporter thought to be involved in the transport of lipids 
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3.3 Functional analysis of knock-out mutant in genes associated with resistance 
To determine if LOF mutations could cause resistance to selected first and second-line drugs we 
acquired a panel of transposon mutants. From the list of 21 genes-associated with unexplained 
resistance, eight genes had 11 representative strains in a single gene knock-out library; 
Tuberculosis Animal Research and Gene Evaluation Taskforce (TARGET) mutant library 
(http://webhost.nts.jhu.edu/target/) (Table 3.3).  
 
The TARGET mutant library consists of strains with a single gene knock-out which is transposed 
with a kanamycin resistant marker.  
 
We performed phenotypic DST using the agar proportion method at the WHO recommended 
critical concentration on these eleven strains against six anti-tubercular drugs. The mutants all 
displayed kanamycin resistance as they all possessed a kanamycin resistance marker in the 
transposon which was used to generate the knockout mutant.  
 
The eleven strains from our phenotypic screen against six first and second-line anti-tuberculous 




Table 3.3: Phenotypic DST of transposon TARGET mutants against anti-tubercular drugs 
(Desjardins et al., 2016) 
Each strain was identified by the gene number (#) and the TARGET mutant library identification 
(ID). Critical drug concentrations listed are represented in µg/mL. S = Susceptible and R = 
Resistance. Drugs tested were isoniazid (INH), rifampicin (RIF), ethambutol (EMB), 




Gene # Lib ID INH 0.2 INH 1 RIF 1 EMB 7.5 STR 2 OFL 2 KAN 6 
Rv0157 JHU0157-1366 S S S S S S R 
Rv0242c JHU0242c-319 S S S S S S R 
Rv1250 JHU1250-1 S S S S S S R 
Rv1375 JHU1375-874 S S S S S S R 
Rv1375 JHU1375-874 S S S S S S R 
Rv1375 JHU1375-141 S S S S S S R 
Rv2088 JHU2088-60 S S S S S S R 
Rv2780 (ald) JHU2780-209 S S S S S S R 
Rv3197A JHU3197A-222 S S S S S S R 
Rv3823c JHU3823c-114 S S S S S S R 
Rv3823c JHU3823c-1817 S S S S S S R 
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3.4 Association of L-alanine dehydrogenase (ald) with D-cycloserine resistance 
The drug resistance screen to rifampicin, isoniazid, streptomycin, ethambutol and ofloxacin 
revealed no hits so we then looked at the function of each of the 21 genes identified in our 
association analysis to see if there were any pointers to which drugs the LOF mutations could be 
causing resistance to. We were intrigued by Rv2780 which encodes for an alanine dehydrogenase 
(ald) that interconverts pyruvate and L-alanine (Figure 1.5). We therefore hypothesised that 
mutations in L-alanine dehydrogenase could lead to changes in alanine flux that could ameliorate 





3.5 Genetic variability of ald in clinical isolates  
To determine if there was a relationship between LOF mutations in ald and drug resistance we 
first looked to see if these mutations only occurred in drug-resistant isolates. Table 3.4 shows the 
11 different LOF mutations in our dataset and the drug-resistant profile of the strains harbouring 
these mutations. There were 7 insertions, 3 deletions and 1 stop codon. These LOF mutations 
occurred exclusively in MDR or XDR strains supporting our idea that ald was implicated in some 
form of resistance. The mutations were also found to have occurred in multiple different lineages 
indicative of convergent evolution. 
 
Table 3.4: Loss-of-function mutations in ald with respect to spoligotype and DST  
For each LOF mutation, the size, type of mutation, nucleotide position or codon number, number 
of isolates in which the mutation occurs, the spoligotype of those isolates, and the level of drug 
resistance of the isolate are listed.  
Polymorphism # isolates Spoligotype DST 
1bp insertion, nt 128 1 LAM4 MDR 
1bp deletion, nt 132 4 T1 MDR (4) 
2bp insertion, nt 133 1 X3 XDR 
2bp deletion, nt 304 1 LAM4 XDR 
1359bp insertion, nt 304 1 LAM4 MDR 
1bp insertion, nt 317 3 X2 MDR (2), poly (1) 
2bp insertion, nt 433 2 LAM4 MDR (1), XDR (1) 
Q153* 1 LAM4 XDR 
1bp deletion, nt 459 8 X3 MDR (4), XDR (4) 
5bp insertion, nt 837 2 LAM4 XDR (2) 







3.6 Development of a growth inhibition assay to evaluate the role of ald mutants in D-
cycloserine resistance   
DST is difficult for D-cycloserine and the only proposed method is testing using LJ medium. 
However, we wanted to test for D-cycloserine resistance in a more controlled medium because 
we were not sure whether levels of L-alanine and other factors could alter metabolism in a way 
that might affect the alanine metabolism pathways, and influence DST. We initially tried the Trek 
Sensititre MYCOTB MIC plate (MYCOTB; Trek Diagnostic Systems, Cleveland, OH), a 
commercially available broth based assay conducted in 96 well plates to determine resistance to 
D-cycloserine. However, we experienced high false positive rates in our control strains. We 
therefore developed a growth inhibition assay using the MGIT system. The principle of the assay 
was to compare the TTP in the presence or absence of drug. MGIT tubes were inoculated based 
on OD but CFU’s were also determined for all inocula to ensure tubes had roughly equivalent 




We initially performed a growth assay in MGIT to determine if there was a growth advantage of 
selected TARGET mutants in the presence of D-cycloserine. The assay was conducted on seven 
of the TARGET mutant stains and CDC1551 which is a fully susceptible laboratory strain. Testing 
was conducted with varying concentrations of D-cycloserine in triplicate. Each strains growth 
was monitored for TTP, a shorter TTP suggests a growth advantage in the presence of D-
cycloserine.  
 
In comparison to CDC1551, only the ald LOF mutant had a significant growth advantage in the 
presence of D-cycloserine at 7.5 μg/mL and 15 μg/mL (p = 0.0075 and 0.0441, respectively). All 
other transposon mutants displayed no significant difference in growth kinetics relative to 
CDC1551 with p > 0.05. This supported our hypothesis that ald LOF mutations causes resistance 
to D-cycloserine. 
 
Table 3.5: Confirmation of growth advantage of transposon TARGET mutants in the 
presence of D-cycloserine is specific to ald loss-of-function (Desjardins et al., 2016) 
 
The MGIT growth assay was performed on CDC1551, the ald LOF mutant and single gene knockouts 
strains in the presence of D-cycloserine. The strains were cultured in triplicate in 0, 7.5 µg/mL and 
15 µg/mL D-cycloserine. The TTP for each strain was recorded in days since inoculation. The standard 
error mean (SEM) of the three replicates is shown above. The mean MGIT TTP and growth inhibition for 
the varying concentrations of D-cycloserine for each mutant strain were statistically compared (using a one-
sided t-test) to CDC1551.  
  
    0 μg/mL 7.5 μg/mL 15 μg/mL 
Gene 
number 








 CDC1551 6.2 0.0212 n/a 16.9 0.8706 n/a 35.2 1.9605 n/a 
Rv2780 
(ald) JHU2780-209 6.3 0.0289 0.8343 8.5 0.4766 0.0075 25.0 0.4527 0.0441 
Rv1250 
JHU1250-1 6.1 0.0289 0.0880 19.0 0.2819 0.9740 41.1 0.5052 0.8844 
Rv1375 
JHU1375-141 6.2 0.0488 0.0994 22.0 0.4455 0.8476 41.6 0.1472 0.8902 
Rv1375 
JHU1375-874 6.0 0.0526 0.0617 22.4 0.3852 0.9627 41.0 0.3046 0.8951 
Rv2088 
JHU2088-60 6.0 0.0367 0.6077 21.6 0.6519 0.9711 41.3 0.3769 0.8997 
Rv3823 
JHU3823c-114 3.4 0.2350 0.0099 16.3 3.1519 0.4588 34.8 0.8177 0.4548 
Rv3823 
JHU3823c-1817 6.3 0.0212 0.9080 19.3 0.8357 0.8403 42.0 0.0000 0.9080 
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3.7 Growth inhibition by D-cycloserine testing of the Δald mutant and control strains   
To confirm if ald LOF conferred resistance to D-cycloserine, we assessed growth inhibition of 
the Δald mutant and appropriate control strains.  
 
We assessed CDC1551 (a fully susceptible reference strain which possessed wild-type ald, ddl 
and alr genes), the ald knockout (Δald) strain and the ald knock-out complemented with wild-
type ald from M. tuberculosis (Δald-comp). The Δald-comp strain was created by cloning the 
H37Rv ald gene onto an integrative vector harboring a kanamycin resistance cassette.  
 
In addition, we included BCG as an additional positive control. BCG is naturally resistant to D-
cycloserine, which may be explained by a cycA point mutation (Chen et al., 2012). BCG also 
possesses a frameshift in ald (Chen et al., 2003, Garnier et al., 2003). To determine the effect of 
the ald frameshift on inhibition by D-cycloserine, we performed our growth assay on M. bovis 
BCG Danish 1331 (BCG) and M. bovis BCG 1331 complemented with wild-type ald from M. 





We performed the D-cycloserine growth assay on the CDC1551 (WT-as represented on the 
graph), the Δald strain, Δald-comp and BCG strains. (Figure 3.1). The Δald strain displayed a 
shorter TTP when compared to wild-type CDC1551 in the presence of D-cycloserine at 7.5 µg/mL 
(P < 0.0001, ANOVA), indicative of a significant growth advantage at this concentration. At the 
15 µg/mL D-cycloserine concentration the Δald strain still showed a growth advantage as 
compared to the wild-type CDC1551(P < 0.0001, ANOVA) but grew slowly relative to the BCG 
strain (P < 0.0001, ANOVA). In addition, we observed that the Δald-comp strain, had greater 
growth inhibition in comparison to the Δald strain (P < 0.0001, ANOVA), but was still inhibited 
significantly less than CDC1551 (P < 0.0001, ANOVA) suggesting that ald complementation 
partially reverted the growth advantage to D-cycloserine at both the 7.5 µg/mL and 15 µg/mL 
concentration. BCG showed minimal growth inhibition when exposed to both low and high dose 
D-cycloserine compatible with its resistant phenotype.  In conclusion, the ald LOF strain 
displayed a growth advantage relative to CDC1551 compatible with a resistance phenotype and 





Figure 3.1: Assessment of laboratory strains TTP in the presence of D-cycloserine. The MGIT growth 
assay was performed on CDC1551 (WT), the Δald-comp, Δald strain, and BCG strains in the presence of 
D-cycloserine. The strains were inoculated in triplicate at the 0, 7.5 μg/mL, 15 μg/mL and 30 μg/mL D-
cycloserine drug concentrations. Each strains TTP was documented as days positive from the time of 
inoculation. Error bars represent the SEM of the mean TTP. Two-way ANOVA was used to calculate the 








The D-cycloserine growth assay was then performed on the BCG and BCG::ald-comp, to evaluate 
the effect of the ald frameshift on growth in the presence of D-cycloserine. At the 7.5 µg/mL D-
cycloserine concentration there was no statistically significant difference in growth between BCG 
and BCG::ald-comp. At the 15 µg/mL and 30 µg/mL D-cycloserine concentrations the BCG::ald-
comp displayed significant inhibition of growth relative to BCG (p < 0.02 and p < 0.0001, 
respectively) (Figure 3.2).  
 
Although we did not fully reverse the resistance phenotype this result suggests ald LOF does play 
a role in D-cycloserine resistance in M. bovis BCG. BCG has a cycA point mutation which is 
implicated in its resistance phenotype, although complementation with cycA only partially 
restored susceptibility suggesting other mechanisms of resistance are involved (Chen et al., 2012). 
The mutation in cycA could therefore explain the modest results of our complementation, but 
differences in the genetic background could also contribute. Experimentation involving the 





Figure 3.2: Complementation of ald in M. bovis BCG prompts slower growth in the presence of high 
dose D-cycloserine. The MGIT growth assay was performed on BCG and BCG::ald-comp strains in the 
presence of D-cycloserine. The strains were inoculated in triplicate at the 0, 7.5 μg/mL, 15 μg/mL and 
30 μg/mL D-cycloserine drug concentrations. Each strains TTP was documented as days positive from the 
time of inoculation. The BCG::ald-comp showed inhibition of growth at higher concentrations of D-
cycloserine. This indicates that ald LOF may contribute to D-cycloserine resistance. Error bars represent 
























































3.8 Growth inhibition by D-cycloserine of clinical isolates with ald mutations   
We next sought to determine whether clinical isolates with mutations in ald and alr exhibited a 
growth advantage in the presence of D-cycloserine. Clinical isolates with varying L-alanine 
dehydrogenase (ald) and alanine racemase (alr) mutations, with diverse drug susceptibility 
phenotypes and varying genetic backgrounds were assessed in the D-cycloserine growth assay. 
They are listed below with their corresponding ald and alr mutations, their DST pattern and 
spoligotype (Table 3.6).  
 
Table 3.6: Clinical isolates tested by the D-cycloserine growth assay with mutations in ald 
and alr genotypes  
 Strain ald alr DST Spoligotype 
TKK-04-0103 WT WT XDR X3 
TKK-01-0019 WT WT XDR LAM3 
TKK-03-0065 WT WT Susceptible Beijing 
TKK-04-0054 WT WT XDR Beijing 
TKK-04-0149 WT WT Susceptible Beijing 
TKK-03-0109 WT WT Susceptible Beijing 
TKK-02-0053 5bp ins at 837 WT XDR LAM4 
TKK-02-0006 Q153* WT XDR LAM4 
TKK-02-0051 2bp ins at 433 WT XDR LAM4 
TKK-04-0071 1bp del at 459 WT MDR X3 
TKK-04-0105 WT Y343T XDR LAM4 
TKK-02-0004 WT K157E XDR LAM4 







The D-cycloserine growth assay was performed in MGIT on these clinical isolates with various 
mutations. At concentrations of 7.5 μg/mL, 15 μg/mL and 30 μg/mL of D-cycloserine, clinical 
isolates with the ald LOF mutation displayed a growth advantage when compared to strains with 
wild-type ald (p < 0.05 at all tested concentrations), demonstrating that the growth advantage seen 
in laboratory strains with ald LOF mutations extends to clinical strains (Figure 3.3).  
 
All three clinical strains with SNPs in alanine racemase also exhibited a growth advantage in the 
presence of 7.5 µg/mL, 15 µg/mL and 30 µg/mL D-cycloserine relative to wild-type strains 
(p < 0.05 at all tested concentrations). When compared to strains with only ald LOF mutations, 
clinical strains with SNPs in alanine racemase did not have significantly different growth at the 
7.5 µg/mL and 15 µg/mL of D-cycloserine but did exhibit a significant growth advantage at 
30 µg/mL of D-cycloserine (p < 0.05). This suggests that at high concentrations of D-cycloserine, 
ald LOF mutations confer less of a growth advantage than the assayed nonsynonymous SNPs in 
the direct target of D-cycloserine, alanine racemase. This in turn indicates that intragenic alr 






Figure 3.3: Assessment of clinical strains TTP in the presence of D-cycloserine. The MGIT growth 
assay was performed on clinical isolates with mutations in ald and alr in the presence of D-cycloserine. 
The strains were inoculated in triplicate at the 0, 7.5 μg/mL, 15 μg/mL and 30 μg/mL D-cycloserine drug 
concentrations. Clinical strains with LOF mutations in ald or polymorphisms in the target of D-cycloserine, 
alr exhibit a shorter time to positivity in the presence of D-cycloserine. Each strain’s TTP was documented 
as days positive from the time of inoculation. Error bars represent the SEM of the mean TTP. Two-way 













































































































3.9 DST of an Δald strain and controls 
Our growth inhibition assay provided a discriminatory tool to test our hypothesis that LOF 
mutations in ald result in D-cycloserine resistance. To be certain we carried out an MIC evaluation 
of our control strains using the only recognized method of DST using LJ medium. 
 
According to the WHO guidelines the critical concentration for resistance on LJ medium was 
lowered to 30 µg/mL (WHO, 2012). When we carried out susceptibility testing on our strains we 
found CDC1551 (WT as represented in Table 3.7) displayed an MIC of 15 µg/mL and was most 
susceptible as compared to the other strains.  The Δald strain showed an MIC of 25-30 µg/mL 
greater than that of CDC1551. The ald-comp displayed an intermediate MIC of 20 µg/mL relative 
to Δald.  
 
The BCG (positive control) strain displayed the greatest resistance with an MIC of 40-60 µg/mL. 
The BCG::ald-comp strain MIC was 40 µg/mL, demonstrating no change to BCG. The M. bovis 
ATCC 19210 strain showed an MIC of 25 µg/mL comparable to that of the Δald strain. We can 
conclude from the MIC testing conducted on these strains that the Δald strain confers a low-level 
of resistance to D-cycloserine.  
 
Table 3.7: The ald loss-of-function mutation confers an increased level of resistance to D-
cycloserine (Desjardins et al., 2016) 
  D-cycloserine MIC (µg/mL) 
 Strain Assay 1 Assay 2 Assay 3 
CDC1551 (WT) 15 15 - 
Δald 25 30 25 
Δald-comp 20 20 20 
BCG  40 40 60 
BCG::ald-comp 40 - 40 
M. bovis ATCC 19210 - 25 25 
 
MIC testing was conducted in three independent experiments to determine reproducibility. Minus (-) signs 




3.10 Contribution of ald, alr, ddlA and cycA mutations to D-cycloserine resistance in 
clinical isolates from KwaZulu-Natal  
Having shown that LOF mutations in ald can cause resistance to D-cycloserine we wanted to 
assess their contribution to resistance relative to other potential drug resistance conferring 
mutations. We therefore examined our dataset for other clinical isolates with mutations in the 
known targets of D-cycloserine, i.e. alanine racemase (alr) and D-alanine:D-alanine ligase (ddlA). 
We identified forty-four clinical strains with varying genetic backgrounds which we then assessed 
for D-cycloserine drug susceptibility using LJ medium. This assay included 22 strains with wild-
type ald, alr, ddlA and cycA alleles, 13 strains which possessed mutations in ald, seven which 
possessed mutations in the alr gene and two which had mutations in both ald and alr genes. Seven 
strains were retested, four of which were outliers. We also assessed the level of resistance in ald 
LOF strains relative to strains which possess mutations in the alr gene.  In our data set we 
observed no clinical isolates with ddlA and cycA mutations, and therefore no DST could be 




Table 3.8: List of clinical isolates with representative mutations and MIC to D-cycloserine 
as determined on LJ media (Desjardins et al., 2016)  
 
a Mutation previously predicted to have high impact on alr function (Köser  et al., 2013). 
b Mutation previously known to confer D-cycloserine resistance (Merker et al., 2013). 
 
Strain Name Spoligotype DST ald alr ddlA cycA LJ MIC
TKK-04-0075 T1 Pre-XDR 1bp del at 132 Y364D WT WT 40
TKK-01-0050 T1 MDR 1bp del at 132 Y364D WT WT 40
TKK-02-0035 X3 XDR 1bp del at 459 WT WT WT 15 (40)
TKK-04-0071 X3 Pre-XDR 1bp del at 459 WT WT WT 40
TKK-04-0040 X2 poly 1bp ins at 317 WT WT WT 20 (20)
TKK-04-0038 LAM 4 Pre-XDR 2bp del at 304 WT WT WT 40
TKK-02-0037 X3 XDR 2bp ins at 133 WT WT WT 30 (40)
TKK-02-0051 LAM 4 XDR 2bp ins at 433 WT WT WT 40
TKK-04-0060 LAM 4 Pre-XDR 2bp ins at 433 WT WT WT 30 (30)
TKK-02-0053 LAM 4 XDR 5bp ins at 837 WT WT WT 40
TKK-02-0049 LAM 4 XDR 5bp ins at 837 WT WT WT 25 (25)
TKK-02-0006 LAM 4 XDR Q153* WT WT WT 40
TKK-04-0122 LAM 4 XDR R15Q WT WT WT 30
TKK-02-0004 LAM 4 XDR WT K133E WT WT 60
TKK-02-0055 Beijing XDR WT L89R WT WT 60
TKK-04-0090 LAM4 mono WT L89R WT WT 40
TKK-04-0105 LAM4 XDR WT M319T 
a WT WT >60
TKK-02-0007 LAM4 XDR WT R373G WT WT 25 (25)
TKK-01-0018 CAS1-Kili poly WT WT WT WT 15
TKK-01-0054 X3 mono WT WT WT WT 20
TKK-01-0084 LAM 4 susceptible WT WT WT WT 40 (40)
TKK-03-0065 Beijing susceptible WT WT WT WT 20
TKK-04-0054 Beijing Pre-XDR WT WT WT WT 20
TKK-01-0007 LAM 3 susceptible WT WT WT WT 15
TKK-01-0033 LAM 4 XDR WT WT WT WT 15
TKK-01-0036 LAM 4 mono WT WT WT WT 30
TKK-01-0060 LAM 3 poly WT WT WT WT 15
TKK-03-0021 T1 susceptible WT WT WT WT 20
TKK-03-0099 X1 susceptible WT WT WT WT 20
TKK-04-0109 LAM 4 XDR WT WT WT WT 20
TKK-04-0149 Beijing susceptible WT WT WT WT 15
TKK-02-0018 T3 Pre-XDR WT WT WT WT 20
TKK-02-0062 CAS1-Kili Pre-XDR WT WT WT WT 15
TKK-01-0019 LAM 3 XDR WT WT WT WT 15
TKK-01-0035 LAM 4 MDR WT WT WT WT 20
TKK-01-0081 LAM 4 susceptible WT WT WT WT 20
TKK-01-0035 LAM 4 MDR WT WT WT WT 20
TKK-02-0050 LAM 4 XDR WT g-8t 
b WT WT >60 (>60)
TKK-04-0103 X3 XDR WT WT WT WT 20
TKK-04-0070 LAM 4 Pre-XDR 1bp ins at 128 WT WT WT 40
TKK-04-0047 LAM 3 poly G213S WT WT WT 30
TKK-03-0026 Unknown susceptible WT A284G WT WT 20
TKK-03-0020 S susceptible WT WT WT WT 20
TKK-03-0029 EAI1SOM susceptible WT WT WT WT 10
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We found that clinical strains with the ald mutations exhibited a median MIC of 40 µg/mL which 
was significantly higher than strains that were wild-type at all of the putative D-cycloserine 
resistance conferring loci. In total 91% of clinical strains which possessed the wild-type alr and 
ald genes had an MIC of ≤ 20 µg/mL. 
 
Two strains (TKK-04-0122 and TKK-04-0047) possessed nonsynonymous SNPs in ald also 
displayed an MIC of 30 µg/mL suggesting these mutations also result in LOF. Taken together 
these results indicate that LOF mutations and nonsynonymous SNPs in ald can result in resistance 
to D-cycloserine at or above the WHO recommended critical concentration of 30 µg/mL. 
 
In our assessment of clinical strains with alr mutations, we found these strains displayed a high 
level of resistance to D-cycloserine in comparison to strains that possessed wild-type alr and ald 
genes. One strain (TKK-02-0050), which possessed a promoter mutation in alr displayed an MIC 
of > 60 µg/mL, which is compatible with a study conducted on M. smegmatis, where it was 
observed that a mutation in the promoter region of alr conferred resistance to D-cycloserine 




Figure 3.4: Distribution of D-cycloserine MIC of M. tuberculosis clinical strains with diverse drug 
susceptibility phenotypes and varying genetic backgrounds (Desjardins et al., 2016). D-cycloserine 
MIC testing was performed on clinical isolates with mutations in ald and alr using LJ medium. This analysis 
includes the strains with wild-type ald and alr genes, LOF mutations in ald, nonsynonymous mutations 
(NSY) in ald and alr genes and promoter mutations (PRO) in alr. Strains which possessed ald and alr 
mutations displayed a significantly greater resistance to D-cycloserine in comparison to strains which 
possessed WT ald and alr. The median of wild-type and ald LOF strains are represented as open circles 
and quartiles are represented as connected bars. The strains with ald LOF displayed greater resistance when 









The objective of this study was to identify novel genes and mechanisms implicated in drug 
resistance in clinical isolates of M. tuberculosis in KwaZulu-Natal. Focussing on LOF mutations 
we were able to provide new insights into the genetic basis of D-cycloserine resistance in clinical 
isolates.  Due to the toxicities (Cunha, 2001, Torun et al., 2005, Mitnick et al., 2008) and severe 
side effects (Kendig et al., 1956, Murray, 1956, Bankier, 1965, Yew et al., 1993) associated with 
the administration of D-cycloserine to patients , it would be particularly worthwhile to develop a 
rapid molecular based assay to detect D-cycloserine resistance. In this way, it would be possible 
to prescribe this drug to patients which actually harbor susceptible M. tuberculosis strains, thereby 
avoiding unnecessary severe drug associated side-effects. In addition, due to technical difficulties, 
phenotypic D-cycloserine DST is not routinely performed (Woods, 2000, Kam et al., 2010, WHO, 
2014). The development of molecular diagnostics would greatly expand the detection of 
resistance to this still widely used second-line anti-tuberculosis drug.  Our results will therefore 
contribute to improved diagnostics for D-cycloserine. 
 
 Based on an association and correlation evolution analyses performed (Desjardins et al., 2016), 
we identified genes with LOF mutations which may be associated with phenotypic resistance. 
From this screening, we focused on ald LOF, which encodes for L-alanine dehydrogenase. Eleven 
different ald mutations were observed in drug-resistant M. tuberculosis clinical strains (Table 
3.4). Distinct ald LOF mutations occurred independently multiple times consistent with 
convergent evolution. This suggests a positive selective pressure. We do not have direct evidence 
that this was D-cycloserine as we do not have detailed drug histories for these patients and many 
of them were primary TB infections. However most of the mutations occurred within resistant 
clinical isolates from Lineage 4 which is associated with the evolution of XDR-TB (Chihota et 
al., 2012, Muller et al., 2013, Cohen et al., 2015). (Figure S1). Patients infected with strains within 
this lineage will have definitely received D-cycloserine therapy. It is therefore highly likely that 
exposure to D-cycloserine was the antibiotic pressure that selected for ald mutations, and our 
experimental validation confirmed mutations in ald confer resistance to D-cycloserine in vitro.  
 
An important part of this study was the development of a reliable assay to assess susceptibility to 
D-cycloserine. Testing on LJ medium is cumbersome and not amenable to more high-throughput 
testing. Our attempts using simple culture in broth were not reliable. So, we optimized a growth 
assay utilizing the BD BACTEC™ MGIT™ 960 system, with titered innocula, which allowed us 
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to evaluate the effects of D-cycloserine on growth in a carefully controlled, sensitive and 
quantitative fashion. This enabled us to show that the Δald possessed a growth advantage in the 
presence of D-cycloserine relative to the wild-type and complemented controls (Figure 3.1). We 
were then able to validate our assay using classical MIC determination on LJ slopes confirming 
ald contributes to D-cycloserine susceptibility in vitro (Table 3.7). 
 
We hypothesised that the mechanism by which ald LOF confers D-cycloserine resistance in M. 
tuberculosis is through the prevention of the conversion of L-alanine to pyruvate, which in turn 
leads to the accumulation of intracellular L-alanine (Figure 1.5). If ald LOF increases available 
L-alanine, then this could reduce the competitive inhibition of alanine racemase and D-alanine 
ligase activity by D-cycloserine through increased substrate availability, which would allow for 
continued cell wall synthesis. At increasing D-cycloserine concentrations drug would eventually 
overwhelm the moderate level of resistance provided by the increased L-alanine pool which is 
what we observed. Metabolomic experiments would be able to test this hypothesis. 
 
Previous work has shown that the innate resistance of M. bovis BCG to D-cycloserine is in part 
due to a SNP in the alanine transporter cycA, but additional genes may be involved (Chen et al., 
2012). Here we hypothesised that the frameshift in ald present in M. bovis BCG (Chen et al., 
2003) might also contribute to D-cycloserine resistance. While complementation of functional 
ald into M. bovis BCG did not affect the MIC to D-cycloserine (Table 3.7) we did see at higher 
concentrations in our growth assay, the growth of complemented strains in the presence of D-
cycloserine was significantly more inhibited than that of M. bovis BCG (Figure 3.2). This suggests 
that ald LOF also contributes to D-cycloserine resistance in M. bovis BCG. It is possible that the 
contribution of ald to D-cycloserine resistance would have greater penetrance in a genetic 
background with the wildtype cycA, and further experimentation could address this. For example, 
the permease cycA probably also transports alanine and mutations in this gene and could therefore 
alter the intracellular flux of L-alanine. The reason the phenotype was not restored may also be 
partly due to an integrative vector being used from which sub-optimal expression is achieved. 
This could also explain why complementation of the ald into the ald knockout strain only partially 
restored a growth advantage with D-cycloserine (Figure 3.1). Further experimentation evaluating 
the overexpression of ald needs validation.  
 
The muted complementation of BCG led us to test M. bovis which also has the same ald mutation 
as BCG. It is generally thought that only BCG is resistant to D-cycloserine but a previous study 
has reported M. bovis to have an elevated MIC (Rist et al., 1967) for D-cycloserine which we 
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confirmed for the reference M. bovis strain ATCC 19210. This prompted us to further evaluate 
other strains of the MTBC, which like M. bovis lack RD9 (Brosch et al., 2002) and which share a 
frameshift mutation in ald. However, experimentation is ongoing and has proven to be difficult 
to conduct as supplementation of pyruvate (required for growth of these strains) was found to 
increase the MIC of D-cycloserine (data not shown). As the ald LOF mutation emerged in the 
RD9 lineage prior to antibiotic therapy, it suggests that the mutation could be selected for in the 
absence of drug. It is however unclear what the adaptive advantage of ald in these strains might 
be, however ald mutations do not lead to a loss of fitness in a mouse model in an M. tuberculosis 
genetic background.  Further experimentation is warranted to obtain conclusions. 
 
Having observed ald LOF causes a moderate level of resistance to D-cycloserine in laboratory 
strains we wanted to determine if this phenomenon was also reflected in clinical strains which 
possessed the ald LOF.  
 
Our data showed, clinical strains (Figure 3.4, Table 3.8) with ald LOF mutations displayed a low-
level of resistance to D-cycloserine. In contrast strains, which harbored non-synonymous and 
promoter mutations in alr displayed a high level of resistance when compared to strains with only 
ald LOF mutations. Clinical isolate, TKK-02-0050 was of particular interest due to this strain 
possessing a promoter mutation in alr, and was predicted to cause resistance from studies 
conducted with M. smegmatis. This mutation most likely causes an upregulation of the alr gene 
and therefore increases the available enzyme which would reduce competitive inhibition by D-
cycloserine. 
 
Testing of our clinical isolates indicated that the majority of the strains with ald LOF mutations 
displayed a median MIC of 40 µg/mL (Figure 3.4, Table 3.8) and it is unclear if this represents a 
clinically significant MIC or not. There is a dearth of studies evaluating how low-level resistance 
conferring mutations effect TB treatment outcomes. In the case of INH resistance the katG 
mutation, S315T, confers high level INH resistance (Wengenack et al., 1997, Saint-Joanis et al., 
1999, Pym et al., 2002, Dalla Costa et al., 2009, Ando et al., 2010) and up to 94% of INH resistant 
clinical strains are known to harbor this mutation in some settings (Musser et al., 1996, Telenti et 
al., 1997, Mokrousov et al., 2002, Morlock et al., 2003, Guo et al., 2006, Muller et al., 2011). The 
inhA promoter mutations are known to confer  low-level  INH resistance and this mutation is 
observed in up to 35% of INH resistant clinical strains (Brossier et al., 2006, Dalla Costa et al., 
2009, Ando et al., 2010, Muller et al., 2011). However, it is still unknown if increasing INH 
concentrations are necessary or can overcome this low-level resistance although a study is 
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currently evaluating this. Similarly, our data show that mutations in ald are associated with low-
level resistance to D-cycloserine and we cannot predict the clinical importance, but increasing D-
cycloserine levels will not be possible due to toxicity.  
 
Two clinical isolates (TKK-04-0075 and TKK-01-0050) harbored both ald and alr mutations. In 
our investigation of D-cycloserine resistance these strains displayed an elevated MIC of 40 µg/mL 
to D-cycloserine (Figure 3.4, Table 3.8). It is possible that ald LOF mutations may represent a 
“stepping stone” mutation to higher level resistance conferred by alterations in the direct targets 
of D-cycloserine.  
 
In two strains which possessed the wildtype ald, alr, ddlA and cycA alleles (TKK-01-0084 and 
TKK-01-0036) we observed an increased MIC to D-cycloserine. These two strains revealed MICs 
of 40 µg/mL and 30 µg/mL (Figure 3.4, Table 3.8) respectively. We propose resistance in these 
strains is not caused by mutations in ald, alr, ddlA and cycA, indicating alternate mechanisms of 
D-cycloserine resistance could exist in M. tuberculosis.  
 
D-cycloserine is an inhibitor of the peptidoglycan biosynthesis pathway, but very little is known 
about it targets. Previous studies have shown that overproduction of alanine racemase and D-
alanine:D-alanine ligase may play a role in D-cycloserine resistance (Chacon et al., 2002, 
Milligan et al., 2007, Chacon et al., 2009, Awasthy et al., 2012). In BCG, resistance to D-
cycloserine may be caused by the polymorphism in the alanine transporter cycA (Chen et al., 
2012). However, none of our characterized clinical strains carried the ddlA and cycA mutations 
that are normally associated with D-cycloserine resistance. This led us to assume that mutations 
in ddlA and cycA may not be of clinical relevance in D-cycloserine resistance. This observation 
shows the value of more accurate genetic characterization of drug targets in a laboratory to predict 
clinically relevant mutations. 
 
In 2008 the recommended WHO D-cycloserine critical concentration was set at 40 µg/mL, as 
verified on LJ medium (WHO, 2008a). The critical concentration was later lowered to 30 µg/mL 
(WHO, 2012). Based on our data, we established a tentative epidemiological cut-off (ECOFF) 
value of 20 µg/mL in our assessment of wild-type strains (Figure S2). ECOFFs are determined 
from analysing MIC distributions of a large number of wild-type strains which possess no known 
drug resistance mechanisms and from patients who have not been exposed to drug (Kahlmeter et 
al., 2003, Kahlmeter and Brown, 2004, Turnidge et al., 2006, Angeby et al., 2012, Kahlmeter, 
2015). Defining ECOFF values is especially important in cases where strains exhibit elevated 
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MICs that do not reach the critical concentration breakpoints (which should be defined on the 
basis of predicting clinical success) (Kahlmeter, 2015). ECOFF values may also be useful in 
circumstances where clinical breakpoints are not known and these values can then be used to 
detect and compare resistance (Kahlmeter et al., 2003, Kahlmeter and Brown, 2004). We observed 
clinical isolates which possess ald LOF mutations are likely to have D-cycloserine MICs close to 
the critical concentration breakpoints that define D-cycloserine resistance, even if they appear to 
be D-cycloserine susceptible according to standard DST methods. This necessitates considering 
ECOFF values in redefining the parameters of resistance, more especially to drugs which exhibit 
low-level resistance mechanisms as observed in our study of D-cycloserine.  
 
However, testing on more wild-type strains in South Africa and other geographical areas is 
required to establish a more concrete ECOFF for D-cycloserine. Our data also suggests the current 
critical concentration of D-cycloserine by WHO standards be re-evaluated (Angeby et al., 2012, 
Torrea et al., 2015). This is necessary as conventional DST methods alone may result in the 
exclusion of isolates exhibiting low-level resistance.  
 
The combination of D-cycloserine or terizidone (a D-cycloserine analogue) with other TB drugs, 
encompasses an important component of the MDR and XDR treatment regimen in South Africa 
(http://www.health-e.org.za/wp-content/uploads/2014/06/MDR-TB-Clinical-Guidelines-
Updated-Jan-2013.pdf). Further examination of the global distribution of ald LOF and other D-
cycloserine resistance conferring mutations will enable an evaluation of the extent of D-
cycloserine resistance in the absence of phenotypic drug resistance testing. Ultimately the 
identification of these mutations will allow studies to determine if they impact on clinical 
outcomes, and provide critical information for the development of rapid genetic based tests for 






Our data is representative of diverse drug resistance profiles of clinical isolates in KwaZulu-Natal. 
We were able to identify potential drug resistance conferring mutations by utilizing whole genome 
sequencing (Cohen et al., 2015, Desjardins et al., 2016). 
 
Our results identified that ald LOF mutations represent a novel resistance mechanism to D-
cycloserine albeit at a low-level of resistance. These strains should therefore be treated with 
attentiveness for resistance, even if they appear to be D-cycloserine susceptible on conventional 
testing methods. They may represent a stepping stone to higher level resistance. The clinical 
implication of these mutations is unknown, but given that D-cycloserine can cause severe 
neurological side effects their presence could be sufficient to exclude D-cycloserine treatment 
where other options are available. 
 
Although our data are from a single province of a single country we have also expanded the 
knowledge of genetic mechanisms of resistance. We have also shown that both alr promoter and 
intragenic mutations are associated with higher levels of resistance to D-cycloserine. We did not 
find ddl or cycA mutations in our data which suggests these genes may be of lesser importance in 
conferring D-cycloserine resistance. 
 
Due to limitations of drug resistance testing in the presence of pyruvate we are currently unable 
to determine if all the RD9 strains of the MTBC have an elevated MIC to D-cycloserine. But this 
seems highly likely in which case ald LOF is a rare example of emergence of a bacterial drug 
resistance conferring mechanisms in the absence of antibiotic selective pressure.  
 
Our work will provide data for the development of novel molecular diagnostics which will allow 
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7H9 Broth  
1. 4.7 g powdered Middlebrook 7H9 broth base was dissolved in 900 mL dH2O. 
2. 5 mL of 40% glycerol was added to the mixture. 
3. Autoclaved at 121C for 15 minutes. 
4. Media was allowed to cool and 100 mL OADC and 2.5 mL 20% Tween 80 added. 
5. Stored at 4C until use, three-week expiration post preparation. 
 
7H10 Agar   
1. 19 g powdered Middlebrook 7H9 broth base was dissolved in 900 mL dH2O. 
2. 12.5 mL of 40% glycerol was added to the mixture. 
3. Autoclaved at 121C for 15 minutes. 
4. Media was allowed to cool to ~65C and 100 mL OADC added. 
5. 25 mL media was poured per petri dish and allowed to cool.  
6. Stored at 4C until use, three-week expiration post preparation. 
 
LB Broth  
1. 25 g powdered LB broth base (Sigma L3522), was dissolved in 1000 mL dH2O. 
2. Autoclaved at 121C for 15 minutes. 
3. Media was allowed to cool and stored at 4C until use, three-week expiration post preparation. 
 
LB Agar  
1. 37 g powdered LB agar base (Sigma L3147), was dissolved in 1000 mL dH2O. 
2. Autoclaved at 121C for 15 minutes. 
3. Media was allowed to cool to ~65C and desired drug added at this interval if required.  
4. 25 mL media was poured per petri dish and allowed to cool.  




SOC medium  
1. 20 g powdered Bacto Tryptone and 5 g Bacto Yeast Extract was weighed out. 
2. The weighed out powders and 2 mL of 5 M KCl and 10 mL of 1 M MgCl2 was dissolved in 
970 mL dH2O. 
3. The medium was autoclaved at 121C for 15 minutes. 
4. Media was allowed to cool to ~ 65C and sterile 10 mL of 1 M MgSO4 and 20 mL of 1 M 
glucose was added.  
5. Stored at 4C until use, three-week expiration post preparation. 
1 M Sodium phosphate buffer (pH 8) (Sambrook and Russell, 2001) 
1. 138 g powdered NaH2PO4.H2O (monobasic; m.w.=138) was dissolved in 1 L dH2O using a 
magnetic stirrer to achieve a 1 M stock concentration.  
2. To a separate flask 142 g powdered Na2HPO4 (dibasic; m.w.=142) was dissolved in 1 L dH2O 
using a magnetic stirrer to achieve a 1 M stock concentration.  
3. To prepare a 50 mL of sodium phosphate buffer at pH 8, add 4.66 mL of 1 M Na2HPO4 and 
0.34 mL of 1 M NaH2PO4 to 45 mL dH2O. 
4. pH was adjusted to 8 with concentrated HCl or NaOH.  
5. Prepared working solutions were filter sterilized using a 0.22-micron filter system. 
6. Stored at room temperature, one-month expiration post preparation. 
 
D-cycloserine antibiotic preparation 
D-cycloserine (Sigma C6880), was prepared freshly in 0.1M Sodium phosphate buffer (pH 8) on 
the day of LJ preparation testing due to instability of the drug. The stock of D-cycloserine was 
prepared and filter sterilised with a 0.22-micron filter. 
 
MGIT supplementation 
The MGIT (Mycobacteria Growth Indicator Tube), contains 7 mL of Middlebrook 7H9 broth 
base (BD BBLTM MGITTM Cat. No. 245122) 
1. To the 7 mL MGIT tubes 800 µL growth supplement which contains OADC (Oleic acid 





Preparation of Löwenstein-Jensen (LJ) medium 
LJ medium is required for mycobacterial culture (Jensen, 1954) and is recommended by the WHO 
(Woods, 2000, Kam et al., 2010). Fresh eggs were used for LJ preparation.  
1. To a sterile flask dissolve 2.4 g monopotassium dihydrophosphate (KH2PO4), 0.24 g 
magnesium sulfate (MgSO4.7H2O), 0.6 g magnesium citrate, 3.6 g L-asparagine in 600 mL 
dH2O. 
2. Autoclaved at 121C for 20 minutes. 
3. To avoid contamination, eggs were cleaned by washing them thoroughly with plain soap and 
rinsed with water. Thereafter the eggs were wiped with 70% ethanol and cracked with a sterile 
knife. A 1000 mL egg homogenate was used. 
4. The egg suspension and 600 mL sterile LJ medium were aseptically mixed and cooled to 
approximately 50-60C.  
5. The appropriate volume of D-cycloserine was added to the LJ tubes prior to inspissation to 
achieve final concentrations of 0, 10, 15, 20, 25, 30, 40, 60, and 120 µg/mL. 
6. The drug containing medium was dispensed in 6 mL amounts into screw cap 15 mL conicals 
and placed in a slanted position on the inspissator at 85C for approximately one hour to set.  





























The ald LOF mutations occurred within drug-resistant clinical isolates from Lineage 4. This 
mutation occurred in 25 MDR and XDR M. tuberculosis strains, indicating that this LOF occurred 
in patients receiving second-line treatment.  
 
 
Figure S1: Pattern of convergent evolution in drug-resistant M. tuberculosis strains (Desjardins et 
al., 2016). A) Distribution of mutations across full length of the ald gene. Position of insertions (blue 
triangles), deletions and nonsense (red triangles) mutations in ald of M. tuberculosis drug-resistant strains. 
Mutations in ald which occur in M. bovis BCG are also displayed. B) Phylogenetic representation of ald 
LOF mutation in Lineage 4 drug-resistant strains. Inner Grey ticks represent MDR M. tuberculosis 
strains. Inner Black ticks represent XDR M. tuberculosis strains. Outer blue ticks represent insertion 






Figure S2: Distribution of D-cycloserine resistance in clinical M. tuberculosis strains (Desjardins et 
al., 2016) This histogram represents distribution of D-cycloserine MICs of the respective M. tuberculosis 
clinical strains according to the different mutations possessed. The current critical concentration (CC) for 
D-cycloserine and tentative epidemiological cut off (ECOFF) are shown. The MICs of BCG and M. bovis 
are also represented on this histogram.  
 
 
 
 
 
